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Resumo 
 
 
 
Resveratrol (RES) tem sido descrito como agente terapêutico para a doença de Alzheimer 
(AD). Dadas as suas diversas vantagens do RES, acredita-se que é útil na terapia da AD. O RES 
apresenta baixa biodisponibilidade, resultante da sua baixa solubilidade em água e rápida 
depuração da circulação torna difícil estabelecer concentrações bioeficazes de RES no sangue 
e tecidos de seres humanos. Portanto, novas estratégias terapêuticas como sistemas de 
entrega de drogas específicas devem ser desenvolvidas a fim de superar essas limitações. Nes-
te trabalho, RES e extratos de grainha e pele de uva foram encapsulados em lipossomas e 
nanopartículas de poli(ácido lático-co-ácido glicólico) (PLGA). Os lipossomas e as nanopartícu-
las de PLGA com tamanhos e propriedades controlados foram preparados utilizando o método 
de hidratação de um fino filme lipídico e evaporação e emulsificação do solvente, respetiva-
mente. Não foram obtidos valores significativos de eficiência de encapsulação para os lipos-
somas. As nanopartículas de PLGA preparadas apresentam uma forma esférica com diâmetros 
entre 158-182 nm, baixos valores de PdI e valores de potencial zeta negativos. Enquanto os 
valores de eficiência de encapsulação do RES encapsulado nas nanopartículas de PLGA foram 
cerca de 80±6%, para os extratos de grainha e pele de uva os valores de eficiência de encap-
sulação obtidos foram ligeiramente inferiores, 75±5% e 74±8%, respetivamente. O sistema 
preparado é estável em condições de armazenamento durante um mês. Os resultados dos 
ensaios de ThT e TEM demonstraram que os fármacos utilizados inibiram a formação das 
fibras Aβ(1-42). Os extratos têm um efeito inibitório mais pronunciado em comparação com o 
RES. Com 40 μM, RES inibe cerca de 86% da agregação do péptido, o extrato de pele de uva 
inibe cerca de 92% e o extrato de grainha de uva inibe cerca de 97%. À concentração de 80 μM, 
estes valores aumentaram para 91, 97 e 98%, respetivamente. Estes resultados sugerem que, 
para além de conter RES que inibe a agregação de Aβ(1-42), os extratos têm outros polifenóis 
que tornam este efeito inibidor mais pronunciado. Os estudos revelaram que as nanopartícu-
las de PLGA carregadas com os fármacos usados também inibiram a formação de fibras de 
Aβ(1-42). À concentração de 40 μM, o RES encapsulado nas nanopartículas de PLGA inibiu cerca 
de 46% da agregação do péptido, o extrato de pele de uva encapsulado nas nanopartículas de 
PLGA inibiu cerca de 52% e o extrato de grainha de uva encapsulado nas nanopartículas de 
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PLGA inibiu cerca de 56%, depois 10 dias de incubação. A partir dos resultados obtidos, foi 
possível concluir que as nanopartículas de PLGA são um nanotransportador adequado para o 
RES e extratos de grainha e pele de uva. Contudo, a otimização destas nanopartículas deve 
ser realizada de modo a aumentar o potencial terapêutico dos fármacos em estudo. 
 
 
Palavras-chave: Doença de Alzheimer, Extrato de grainha de uva, Extrato de pele de uva, 
Lipossomas, Nanopartículas de PLGA, Resveratrol. 
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Abstract 
 
 
 
Resveratrol (RES) has been suggested as therapeutic for Alzheimer Disease (AD). Given 
their many benefits of RES, it is believed that it is useful in the therapy of AD. RES has low 
bioavailability, resulting from its low solubility in water and rapid clearance from the circu-
lation of RES make difficult to establish bio efficacious concentrations of RES in the blood 
and tissues of humans. Therefore, new therapeutic strategies, as specific drug delivery sys-
tems, must be developed in order to overcome those limitations. In this work, RES and grape 
seed and skin extracts were encapsulated in liposomes and poly(lactide-co-glycolide) nano-
particles (PLGA NPs). Liposomes and PLGA NPs with controlled sizes and properties were pre-
pared using the hydration of a thin lipid film method and the single emulsion solvent evapo-
ration methods, respectively. No significant values of encapsulation efficiency were obtained 
for liposomes  The prepared PLGA NPs exhibit a spherical shape, mean diameter between 158 
to 182 nm, low PdI values and negative zeta potential values. While RES entrapment reached 
values of efficiency of approximately 80±6 %, for grape seed and skin extracts-loaded PLGA 
NPs the attained encapsulation efficiency values were slightly lower, 75±5 % and 74±8 %, re-
spectively. The prepared system is stable at storage conditions for one month. ThT binding 
assay and TEM results demonstrated that the drugs used inhibit the Aβ(1-42) fibril formation. 
The results indicated that the extracts have a more pronounced inhibitory effect in compari-
son with RES. At the concentration of 40 μM, RES inhibits around 86% of the aggregation of 
the peptide, the grape skin extract inhibits around 92% and the grape seed extract inhibits 
around 97%. At the concentration of 80 μM, these values increased for 91, 97 and 98%, re-
spectively.  These results suggest that beyond to contain RES that inhibits the aggregation of 
Aβ(1-42), the extracts have other polyphenols that make this inhibitory effect most pro-
nounced. The studies proved that drug-loaded PLGA NPs inhibit the Aβ(1-42) fibril formation. 
At the concentration of 40 μM, RES-loaded PLGA NPs inhibits around 46% of the aggregation 
of the peptide, the grape skin extract-loaded PLGA NPs inhibits around 52% and the grape 
seed extract-loaded PLGA NPs inhibits around 56%, after 10 days of incubation. From the at-
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tained results, it was possible to conclude that PLGA NPs formulation is a suitable 
nanocarrier for RES and extracts of grape seed and skin. But, the optimization of NPs must 
be performed in order to increase the therapeutic potential of the drugs under study. 
 
 
Keyword: Alzheimer disease, Grape seed extract, Grape skin extract, Liposomes, PLGA NPs, 
Resveratrol. 
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Chapter 1 
 
 
Introduction 
 
 
 
1.1 - Motivation 
 
The incidence of Alzheimer’s disease (AD), a neurodegenerative disorder, is promoted by 
the increase of the age. This disease affects the memory and other cognitive functions with 
sufficient intensity to produce a functional loss, and it is the most common cause of dementia 
in the elderly (Brookmeyer, et al., 2007). AD is a progressive disease and is characterized by 
loss of memory and cognitive impairment, loss of language and behavior changes. The 
neuropathological characteristics of AD include extracellular senile plaques, which consist of 
deposits of amyloid beta-peptide (Aβ) and neurofibrillar tangles that are formed by 
hyperphosphorilation and abnormal deposition of tau protein (Clippingdale, et al., 2001) 
(Klafki, et al., 2006) (Selkoe, 2001). The imbalance between Aβ production and its clearance 
leads to the Aβ aggregation in the brain, that plays a key role in the development of AD (Li, 
et al., 2012). 
Insoluble fibrillar protein aggregates are considered a pathological feature of several neu-
rodegenerative diseases such as AD, PD and Huntington’s disease (HD). Protein misfolding or 
partially folded structure is responsible for the fibrillation of various amyloidogenic pro-
teins/peptides (Ahn, et al., 2007). Thus, it is essential to find molecules that prevent or in-
terrupt the aggregation of proteins (Feng, et al., 2009). A key aspect to be considered is if 
these molecules have the ability to cross the blood-brain barrier (BBB). 
Various natural compounds have been suggested as therapeutics for AD and PD. Among 
these compounds, resveratrol (RES) (the major phenolic constituent of red wine) arouses 
great interest (Amri, et al., 2012). RES has interesting biochemical and physiological proper-
ties such as antioxidant, anti-inflammatory, anticarcinogenic, analgesic, cardioprotective, 
chemo-preventive, anti-aging activities and neuroprotective (Ahn, et al., 2007) (Baur & Sin-
clair, 2006). Several studies have demonstrated that RES is capable of preventing a variety of 
disorders, including cardiovascular diseases, cancer, diabetes, arthritis and neurodegenera-
tive diseases. Given the benefits of RES, it is believed that it is useful in the therapy of AD 
and PD (Gusman, et al., 2001). RES has anti-amyloidogenic activity because it promotes the 
intracellular degradation of Aβ by a mechanism involving the proteasome, thereby reducing 
levels of Aβ (Marambaud, et al., 2005). 
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A growing effort has being applied to find novel approaches for neurodegenerative treat-
ment and in recent years a growing number of studies, focused on the research and develop-
ment of nanoparticles as drug delivery systems, have been conducted (Wilczewska, et al., 
2012). Liposomes and PLGA have different physico chemical, biochemical and mechanical 
properties each presenting their own advantages where drug delivery is concerned. As the 
success of a neurodegenerative disease therapy depends not only on the pharmacokinetic and 
pharmacodynamic activity of the therapeutic agent, but to a large extent, on its bioavailabil-
ity and toxicity (Acharya & Sahoo, 2011), the development of a nanocarrier for RES will allow 
to enhance its therapeutic activity. 
 
 
1.2 - Main Objectives 
 
The main aim of the present work is to develop suitable nanoparticles (NPs) for drug de-
livery system for RES and extracts of seed and skin of grape. For that purpose, first, the phys-
icochemical properties of RES and the extracts of seed and skin of grape were assessed: sta-
bility at different temperatures and pH’s. Liposomes and PLGA nanoparticles with controlled 
sizes and properties were prepared in this study, as nanocarriers of RES and extracts of seed 
and skin of grape. Their synthesis was complemented with physicochemical characterization 
of structure and properties. The effect of RES and extracts of seed and skin of grape on Aβ 
was studied. 
 
 
1.3 – Thesis Organization 
 
This dissertation is organized into seven chapters. This chapter, “Introduction”, presents 
the subject and main objectives of this research work. Chapter 2, “State of the art”, presents 
an overview of the AD, the function and importance of the BBB and drug delivery system that 
target Aβ namely liposomes and PLGA NPs. Lastly, a review of the RES and their effects on AD 
and PD. Chapter 3, “Characterization of Resveratrol" the physicochemical properties of RES 
were assessed: stability at different temperatures and pH. Chapter 4, "Nanocarriers Prepara-
tion and Characterization", describes the methodology involved in the preparation and char-
acterization of the liposomes and PLGA NPs. Chapter 5, "Interaction of Amyloid-Beta with 
Resveratrol", presents and discusses the interaction study of Aβ1-42 with RES and extracts of 
seed and skin of grape. Chapter 6, "Conclusions" summarizes the main findings of this research 
work. 
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Chapter 2 
 
 
State of the Art 
 
 
 
2.1 – Alzheimer’s Disease 
 
The increase of the age promotes incidence of neurodegenerative diseases. These diseas-
es destabilize significantly the memory and other cognitive functions with sufficient intensity 
to produce a functional loss, such as carrying out everyday activities or recognizing people 
and places (Brookmeyer, et al., 2007). 
AD is known as the most important neurodegenerative disease. In 1906 was described by a 
German neurologist, Alois Alzheimer, and received that designation in 1910 by Kraeplin. AD is 
characterized by severe loss of cognitive ability, with decreased declarative memory and 
communication difficulties as well as psychiatric symptoms such as apathy, spatial disorienta-
tion, general disinterest and depression and agitation/aggression. The latter symptom is re-
flected in the early stage of the disease (Gaggelli, et al., 2006). A loss of emotional control is 
observed frequently in patients with AD, a symptom that is accompanied by physical or verbal 
aggression. With de evolution of the disease, people develop motor problems and present dif-
ficulty for walking and execute simple activities. By the time, the disease causes a progres-
sive decline of the memory and cognition, leading to the immobility of the patients that suc-
cumb to respiratory difficulties (Larson, et al., 2004). This disease is progressive and for now 
irreversible. AD affects the central nervous system with psychological and physiological con-
sequences (Blennow, et al., 2006). 
AD affects individuals of any age but, normally, this disorder appears among people over 
the age of 65 years, with an average of eight year living after the appearance of the first 
symptoms (Larson, et al., 2004). Between 50-70% of people with dementia have this disease 
and affects about 4-10% of the population between 65 and 75 years, 10-35% between 75 and 
85 years and 50% in people over 85 years (Brookmeyer, et al., 2007) (Gaggelli, et al., 2006). 
In real numbers, the annual incidence of dementia for AD in the United States is 350 000 cas-
es. In European Union countries, the incidence rises to 600 000 annual cases, numbers that 
exceed the cerebral vascular accident, diabetes mellitus and breast cancer (Kalaria, et al., 
2008). AD currently affects over 35 million people worldwide (Ferri, et al., 2005). With in-
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creasing mean life expectancy, it is expected that this number will increase to 66 million by 
2030 and 140 million in 2050 (Brookmeyer, et al., 2007). 
The AD has two histopathological markers: neurofibrillary tangles and senile plaques (or 
amyloid plaques) (Clippingdale, et al., 2001) (Klafki, et al., 2006). Senile plaques consist of 
deposits of Aβ whereas neurofibrillary tangles are formed by hyperphosphorilation and ab-
normal deposition of tau protein (Clippingdale, et al., 2001) (Klafki, et al., 2006) (Selkoe, 
2001). The peptide is aggregated as amyloid fibrils within the neuritic plaques and vascular 
deposits (Selkoe, 2001). Scientific evidences from genetic and animal models have established 
a causative role of Aβ in AD (Hardy & Selkoe, 2002). 
The AD brain exhibits modified morphology, including enlargement of the ventricular sys-
tem and atrophy of the frontal, temporal and parietal cortex together with the hippocampus 
and amygdale (Alves, et al., 2012). Initially, the senile plaques appear in the frontal cortex, 
and then spread throughout the cortical region. Hyperphosphorylated tau and insoluble tan-
gles appear first in limbic system (entorhinal cortex, hippocampus, dentate gyrus), and then 
in the cortical region. Tangles appear before deposition of plaques being most associated with 
the severity of the disease than the amount of senile plaques (Hardy & Selkoe, 2002).  
The AD still does not have cure, so treatment aims only to control their symptoms. The 
medications used include Rivastigmine, Donepezil, Galantemina and Memantine (Blennow, et 
al., 2006) (Kalaria, et al., 2008). 
Evidence supports the existence of a direct relationship between the degree of dementia 
patients who have AD, and the concentration of soluble aggregates of the Aβ peptide (Lee, et 
al., 2004). Aβ is derived by proteolytic cleavage of the β-amyloid precursor protein (APP) by 
sequential activities of β- and γ–secretases. This process is explained by a theory has been 
formulated for 25 years: a cascade hypothesis (Clippingdale, et al., 2001) (Hardy & Selkoe, 
2002) (Ladiwala, et al., 2012). 
 
2.1.1 - Amyloid Cascade Hypothesis  
The amyloid cascade hypothesis (ACH) is the most influential model of the AD pathology 
proposed over the last 25 years. The identification of Aβ in senile plaques and genetic studies 
that identified mutations in the APP, presenilin 1 (PSEN1), and presenilin 2 (PSEN2) genes 
leading to the accumulation of Aβ, resulted in the original formulation of the ACH (Reitz, 
2012). As a consequence of these observations, the presence of Aβ within senile plaques was 
interpreted as an effect of these mutations that subsequently leads to cell death and demen-
tia (Armstrong, 2011) (Hardy & Selkoe, 2002) (Karran, et al., 2011) (Korczyn, 2008) (Reitz, 
2012) (Sommer, 2002). 
The amyloid cascade hypothesis (Figure 2.1) suggests that dysfunction and neuronal death 
in the brain is caused by the deposition of Aβ. In the original hypothesis, it is proposed that 
this neuronal dysfunction and death was caused by the deposition of Aβ fibrils in amyloid 
plaques. As knowledge of pathological changes in AD increased, research focused on more 
specific alterations in Aβ processing, such as the cleavage of APP into Aβ peptides (Aβ1–40 and 
Aβ1–42) and the importance of Aβ oligomers (small aggregates of 2 to 12 peptides) (Armstrong, 
2011) (Klafki, et al., 2006) (Sommer, 2002). 
The cascade of Aβ peptide aggregation involves conformational transitions of α-helices to 
β-sheets. In vitro studies indicated that this transition conformation plays a key role in the 
formation of amyloid fibrils. Initially, Aβ monomers are converted into soluble aggregates 
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ALZHEIMER’S DISEASE 
Aβ oligomers 
Aβ protofibrils 
designated oligomers that have a β-sheet structure. Oligomers aggregate forming protofibrils 
and the aggregation of these protofibrils originates insoluble fibrils. The transition of antipar-
allel to parallel β –sheet results of the conversion of oligomers into fibrils (Armstrong, 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 - Representation of the amyloid cascade hypothesis. Adapted from (Ahmed, et al., 2010). 
 
Tau, a microtubule-associated protein, is the major constituent of neurofibrillary tangles. 
The amyloid cascade hypothesis suggests toxic concentrations of Aβ cause changes in tau pro-
tein and subsequent formation of neurofibrillary tangles (Small & Duff, 2008). Tau is a soluble 
protein, but insoluble aggregates are produced during the formation of neurofibrillary tangles, 
which disrupt the structure and function of the neuron. Initially, Tau monomers bind and 
form oligomers, which then aggregate into a β-sheet before form the neurofibrillary tangles 
(Hardy & Selkoe, 2002) (Meraz-Ríos, et al., 2010). 
Aβ derived from the proteolytic cleavage of APP, a protein that has the general properties 
of a cell surface receptor. The APP gene, located on chromosome 21, codes for multiple 
isoforms of a glycoprotein that contain a single membrane spanning sequence, a long N-
terminal extracellular region and a short C-terminal cytoplasmic tail that is expressed in 
many tissues and concentrated in the synapses of neurons. This protein can be processed 
through two main pathways: non-amyloidogenic and amyloidogenic. In the non-amyloidogenic 
pathway, alpha-secretase, a proteolytic enzyme, cleaves APP in its transmembrane region 
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resulting in a soluble fragment of APP and a carboxy-terminal fragment C83. For the 
amyloidogenic pathway, the APP cleavage produces the Aβ peptide through the sequential 
action of β- and γ-secretase (Clippingdale, et al., 2001). After processing of APP by β- and γ-
secretase, Aβ is secreted and aggregates into fibrils that deposit in senile plaques. Fibrils and 
plaques can induce neurotoxicity directly or indirectly, e.g. by the formation of neurofibrilla-
ry tangles (Armstrong, 2011) (Klafki, et al., 2006) (Sommer, 2002).  
Originally it was thought that Aβ was a product of the abnormal cleavage, but now it is 
known that Aβ has been established as a normal metabolic product that is found in cerebro-
spinal fluid and serum of healthy individuals. The regulatory activity of three different 
proteolytic enzymes, α-, β- and γ -secretase, in their specific cleavage sites produces various 
products, including Aβ1-40 and Aβ1-42 (Lee, et al., 2004). The most abundant forms of Aβ pep-
tide have 40 (~90%) and 42 (~10%) amino acids (a.a.). The Aβ1-42 is characteristically produced 
by cleavage in the endoplasmatic reticulum, while the Aβ1-40 normally is produced by cleavage 
in the trans-Golgi network. Aβ1-42 is the main specie of Aβ present in the nucleus of senile 
plaques although Aβ1-40 is the predominant product of this proteolytic pathway and is found 
mainly in cerebrovascular amyloid deposits (Hardy & Selkoe, 2002). The deposition of Aβ1−40 
and Aβ1−42 into senile plaques begins with the nucleation of soluble Aβ1−42 into fibrils followed 
by accumulation of normally soluble Aβ1−40 (Lee, et al., 2004). The Aβ1–42 peptide aggregates 
fast than Aβ1–40, and the ratio of these two isoforms is influenced by the pattern of cleavage -
from APP by α-, β-, and γ-secretases (Hardy & Selkoe, 2002).  
Several potential risk genes for AD have been identified, with the apolipoprotein E (ApoE) 
considered to be the most consistent. The ApoE gene represents the major genetic risk factor 
for AD. Humans have three common ApoE alleles: ApoE2, ApoE3 and ApoE4. ApoE4 allele can 
bring forward considerably the age of disease onset, ApoE3 can be considered to be neutral 
and ApoE2 is thought to be protective. The apoE4 triggers the Aβ fibrillogenesis by accelerat-
ing the development of AD and ApoE3 binds to tau protein (whose their function is believed to 
be related to stabilization of neuronal microtubules), reducing the rate of phosphorylation 
and the consequent development of filaments (Blennow, et al., 2006) (Gaggelli, et al., 2006). 
The apoE protein acts as a carrier for cholesterol brain. Cholesterol modulates the processing 
of APP by increasing the enzyme β-secretase activity, resulting in increased production of Aβ, 
leading to increasing deposits of amyloid. On the other hand, the apoE2 has a positive effect 
on memory and then is protective against the development of AD. The apoE4 appears to have 
a neurotoxic role leading to neurodegeneration and accelerates the deposition of Aβ. Thus, 
the interaction between Aβ, apoE4, cholesterol and APP forms a cascade of events that cul-
minate in the pathogenesis of AD (Selkoe, 2001). 
Individuals with two ApoE4 alleles have more than seven times increased risk of develop-
ing AD compared with those with ApoE3 alleles (Korczyn, 2008). 
 
 
2.2 – Drug Delivery Systems to Cross the Blood Brain Barrier 
 
The transport of the majority of drugs from the blood to the brain is impeded by BBB. The 
BBB is composed of a monolayer of brain capillary endothelial cells and its main function is to 
protect the brain against toxic substances (Alam, et al., 2010) (Huang, et al., 2013) (Boer & 
Gaillard, 2007). This BBB function results from the combination of the physical barrier, 
transport barrier (specific transport mechanisms mediating solute flux), and metabolic barrier 
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(enzymes that metabolizing molecules in transit) (Abbott, et al., 2006) (Loscher & Potschka, 
2005) (Hervé, et al., 2008). Thus, the presence of the BBB difficult the development of new 
treatments for brain diseases (Pardridge, 2003) (Pardridge, 2012) (Pardridge, 2005). The 
global market of the drugs for the CNS needs to grow over 500% in order to be compared to 
the world market for cardiovascular drugs (Pardridge, 2002). 
Nearly 100% of large-molecule drugs do not cross the BBB. Also the smaller molecules 
cross the BBB have difficulties in crossing the BBB. About 98% of them cannot cross this barri-
er (Lipinski, 2000) (Pardridge, 2003). For a small-molecule drug to cross the BBB in pharmaco-
logically significant amounts, the molecule must have two molecular characteristics: 1) high 
lipid solubility and 2) low molecular mass (<400-500 Daltons) (Pardridge, 2003). Currently 
there are only four classes of CNS disorders that are treated with small molecule drug: de-
pression, schizophrenia, chronic pain and epilepsy (Lipinski, 2000) (Pardridge, 2003) 
(Pardridge, 2005). Still, there is no neurotherapy to stop the neurodegeneration that occurs in 
the AD and PD (Zivadinov, et al., 2003). 
Until now, several nanoparticles (NPs) have been developed to protect and transport the 
desired molecules to the brain (Ramos-Cabrer & Campos, 2013). NPs are nanoscaled particles 
(10-1000 nm), composed by natural or synthetic polymers. They interact with biological barri-
ers crossing them easily and they are used to target and deliver drugs in a controlled manner. 
The NPs have proven to be the best vehicles to deliver drugs to biological systems in different 
neurodegenerative diseases due to their ability to cross the BBB (Liu, et al., 2012). NPs can 
be classified in reversible or irreversible complexes. The reversible NPs are supramolecular 
complexes formed by noncovalent intermolecular interactions as van de Waals forces or lipo-
philic interactions. Liposomes are one example of this type of nanoparticle (Ramos-Cabrer & 
Campos, 2013). Dendrimers, nanocapsules, nanospheres, nanocages and nanotubes are exam-
ples of non-reversible NP that comprise molecules with strong molecular interactions like co-
valent or metallic bonds, presenting great stability (Alam, et al., 2010) (Ramos-Cabrer & 
Campos, 2013). 
The encapsulation of the drug into the particle is made by incorporating the molecule 
during the NPs production (Danhier, et al., 2012), preventing agglutination of the drug with 
plasmatic proteins or its retention in the liver, spleen, lungs, and others (Brigger, et al., 
2002) (Kumari, et al., 2010). Sometimes is necessary to change the NPs surface for that can 
cross the BBB. The modifications strategies can be based on: a) covalent attachment of poly-
ethylene glycol (PEG), b) coating with certain surfactants that should have PEG fragments in 
their structure and c) covalent attachment or adsorption of targeting molecules (Wohlfart, et 
al., 2012). 
 
2.2.1 - Liposomes   
Liposomes are vesicles formed by one or more phospholipid bilayers concentrically orient-
ed around an aqueous compartment. This structure act as a drug carrier (Anwekar, et al., 
2011) (Huang, et al., 2013) (Torchilin, 2005). These structures are formed by amphiphilic 
compounds that have a polar structure capable of interacting with water and a nonpolar re-
gion which tends to protect yourself from contact with water (Figure 2.2) (Shashi, et al., 
2012). Liposomes allow the encapsulation of hydrophilic and/or lipophilic substances.  Hydro-
philic substances remain in the aqueous compartment while lipophilic substances are ab-
sorbed by the lipid membrane (Huang, et al., 2013) (Torchilin, 2005). Liposomes are spherical 
  
8 
 
 
 
lipid particles of variable size, just visible using high resolution microscopes (Malam, et al., 
2009). 
 
 
 
 
 
 
 
 
Figure 2.2 - Schematic representation of a liposome structure. 
 
Liposomes may present different sizes, from small unilamellar vesicles (SUVs) with diame-
ters less than 100 nm until multilamellar vesicles (MLVs) with diameters between 100 and 
1000 nm. SUVs are preferred for the efficient and continuous drugs release (Liu, et al., 2012). 
The controlled release systems of pharmaceuticals have been the subject of research in 
the last four decades. Liposomes membranes have the ability to fuse with cell membranes 
and then release their content into the cytoplasm. Liposomes are optimal carriers for the en-
trapment and cellular delivery of drugs and are able to promote a controlled release of the 
drugs at the target site over a prolonged period of time (Manconi, et al., 2007). Such 
nanocarriers are considered excellent systems for drug controlled release due to their struc-
tural flexibility, size, composition and fluidity/permeability of the lipid bilayer versatility. 
Another advantage is that they are able to incorporate a variety of both hydrophilic and hy-
drophobic compound. In general, encapsulation and retention of active substances in lipo-
somes depend on the nature and concentration of the phospholipids, the concentration of the 
substance concerned and the conditions for obtaining liposomes (Mufamadi, et al., 2010).  
The main advantage of the liposomes is that resemble the structure of cell membranes. 
Therefore, these particles effectively interact with cells and tissues. In addition, liposomes 
are non-toxic, biodegradable (Gonçalves, et al., 2014) (Salvati, et al., 2013) (Sirisha, et al., 
2012) (Torchilin, 2005) and can be prepared synthetically at high purity (Schnyder & Huwyler, 
2005).  
PEG molecules are added to increase the stability and bioavailability of the systems while 
protecting the liposomes from clearance by cells of the reticuloendothelial system (Torchelin, 
et al., 1994). These drug delivery systems increase the half-life up to 90 hours in humans, due 
to a reduced absorption by the liver and spleen (Gabizon, et al., 2003). Cholesterol is also 
added to the formulations to increase the circulation time of the liposomes in the blood 
through the increase of their stability (Gabizon, et al., 2003) (Upadhyay, 2014). 
 
2.2.2 – PLGA Nanoparticles   
Several studies have been conducted about drug delivery by biodegradable polymers. 
Amongst all the biomaterials, application of the biodegradable polymer poly (lactic-co-
Hydrophobic tail 
 
Hydrophilic head 
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H+ 
glycolic acid) (PLGA) has shown immense potential as drug delivery carrier and as scaffold for 
tissue engineering. PLGA is a co-polymer of poly lactic acid (PLA) and poly glycolic acid (PGA) 
linked by ester bonds (Figure 2.3) physically strong and highly biocompatible that has been 
extensively studied as delivery vehicle for drugs, proteins genes, vaccines, antigens, human 
growth factors and various other macromolecules such as DNA, RNA and peptides (Acharya & 
Sahoo, 2011) (Makadia & Siegel, 2011). PLGA is most popular among the various available bio-
degradable polymers due to their nontoxic behavior, stability in blood, nonthrombogenic, 
nonimmunogenic, noninflammatory, do not activate neutrophils, excellent biocompatibility, 
and biodegradability properties, long clinical experience, favorable degradation characteris-
tics, possibilities for sustained drug delivery and its hydrolysis leads to metabolite monomers, 
lactic acid and glycolic acid (Figure 2.4) (Acharya & Sahoo, 2011) (Kumari, et al., 2010) 
(Makadia & Siegel, 2011). Because these two monomers are endogenous and easily metabo-
lized by the body via the Krebs cycle, a minimal systemic toxicity is associated with the use of 
PLGA for drug delivery or biomaterial applications (Acharya & Sahoo, 2011) (Kumari, et al., 
2010). 
 
Figure 2.3 - Chemical structure of poly (lactic-co-glycolic acid). x represents the number of lactic acid 
units and y is the number of glycolic acid units. 
 
PLGA is soluble in wide range of common solvents including chlorinated solvents, 
tetrahydofuran, acetone or ethyl acetate. In water, PLGA biodegrades by hydrolysis of its es-
ter linkages (Figure 2.4). During hydrolysis the increasing number of free carboxylic end-
groups lead to matrix swelling and increasing of hydrophilicity, which enhances water-uptake 
(Wischke & Schwendeman, 2008). These acidic products accumulate inside the PLGA NPs and 
are responsible for reaction auto-catalysis (Klose, et al., 2008) (Wischke & Schwendeman, 
2008). The hydrolytic breakdown also causes the formation of pores in the matrix of the pol-
ymeric system (Cohen, et al., 1991). The change in PLGA properties during polymer biodegra-
dation influences the release and degradation rates of incorporated drug molecules (Makadia 
& Siegel, 2011). 
 
 
 
Figure 2.4 - Representation of hydrolytic degradation of PLGA and its products. Adapted from (Danhier, 
et al., 2012). 
 
PLGA 
+ 
Lactic acid Glycolic acid 
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Although not causing tissue damages, PLGA NPs are not able to remain for a long time in 
blood stream because they are usually recognized by the immune system. Though, the size of 
the PLGA NPs influences the blood circulation time (Acharya & Sahoo, 2011). If the system is 
smaller than 100 nm, the plasma protein adsorption to the NP surface is almost negligible, 
and the immune system is unable to eliminate NPs. For NPs over 100 nm, their surface must 
be functionalized with biomolecules to increase blood circulation half-life. One of the most 
used strategies is coating their surface with a biodegradable copolymer with hydrophilic char-
acteristics such as polyethylene glycol (PEG) (Wang, et al., 2009). 
Several studies have investigated the mechanism of intracellular drug delivery by PLGA 
NPs. PLGA NPs are internalized in cells partly through fluid phase pinocytosis and also through 
receptor-mediated endocytosis. The acidic medium of late endosome triggers a charge 
change in PLGA NPs. The NP becomes cationic leading to destabilization of late-endosomal 
membrane allowing efflux of NP and drug release (Figure 2.5). PLGA NPs rapidly escape the 
endosome-lysosomes and enter the cytoplasm. This facilitates interactions of NPs with the 
vesicular membranes leading to transient and localized destabilization of the membrane re-
sulting in the escape of NPs into the cytosol (Acharya & Sahoo, 2011) (Vasir & Labhasetwar, 
2007). Endosome-lysosome pathway is characterized by two types of compartments, the en-
dosome and lysosome. Lysosomes are usually regarded as the terminal degradation compart-
ment of this pathway. One important feature of PLGA NPs is that they are cationic only in the 
endosomal compartment and do not destabilize the lysosomes, unlike another kinds of NPs. 
This allows reducing their toxicity (Acharya & Sahoo, 2011).  
 
 
 
 
Figure 2.5 - PLGA NPs endolysosomal efflux and drug release. Adapted from (Danhier, et al., 2012). 
 
Several factors affect the PLGA NPs release profile such as: 1) drug’s chemical structure 
and its interactions with PLGA; 2) physico-chemical properties of the encapsulated drug; 3) 
geometry of drug-loaded PLGA NPs (size and shape); 4) drug solubility and 5) loading efficien-
cy (Cohen, et al., 1991) (Kumari, et al., 2010) (Wang, et al., 2009). The main pathways for 
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drug release in PLGA NPs are: 1) desorption of drug bound to the surface, 2) diffusion through 
NP matrix, 3) NP matrix hydrolysis, 4) or a combined degradation-diffusion process (Cohen, et 
al., 1991) (Klose, et al., 2008) (Kumari, et al., 2010) (Makadia & Siegel, 2011). PLGA NPs gen-
erally exhibit a biphasic release profile, characterized by an initial burst due to the release of 
surface-adsorbed drugs followed by a biodegradation-accelerated release until complete pol-
ymer solubilization (Kawasaki & Player, 2005) (Kumari, et al., 2010). This final phase is a 
combination of biodegradation-diffusion process. This final phase is a combination of biodeg-
radation-diffusion process (Kawasaki & Player, 2005). This controlled and sustained release 
prevents high doses of drug accumulation. Also, the slow release allows a decrease of the 
administration frequency, since drug levels are maintained over long periods of time (Kumari, 
et al., 2010). 
Despite of being widely used in medical applications, the PLGA NPs use faces a few limita-
tions as their poor loading capacity. The burst release mentioned above can be a big disad-
vantage since large amounts of drug are lost before reaching the target tissue, resulting in an 
efficacy loss of the delivery of drugs. Also, the many required steps for NPs production such 
as centrifugation and dialysis are expensive and difficult to scale-up (Danhier, et al., 2012). 
PLGA NPs also exhibit a size-dependent cytotoxicity. Small PLGA NPs may trigger the genera-
tion of reactive oxygen species, mitochondrial depolarization and inflammatory cytokines re-
lease. Therefore, some studies indicate that PLGA NPs larger than 100 nm are safer for bio-
medical applications (Xiong, et al., 2013). Another drawback of these NPs is the entrapment 
of hydrophilic drugs, since those drugs rapidly partition into the aqueous phase during NPs 
preparation. Therefore is necessary to use appropriate preparation methods as the double 
emulsion technique (Makadia & Siegel, 2011). Finally, it is essential to functionalize the NP 
surface in order to achieve a maximum efficacy (Wang, et al., 2009). 
 
 
2.3 – Resveratrol 
 
RES (C14H12O3), chemically known as 3, 5, 4’ - trihydroxystilbene is a natural non-flavonoid 
polyphenolic compound present in over than 70 species of plants including vegetables, fruits, 
grains, roots, flowers, seeds, tea and wine (Amri, et al., 2012) (Chachay, et al., 2011). As 
more intense the color, higher is the amount of polyphenols (Li, et al., 2012). Chemically, RES 
has two geometrical isomers (Figure 2.6), trans-RES and cis-RES, with the trans form as the 
biologically active form (Filip, et al., 2013). RES is a highly photosensitive compound suscep-
tible to UV-induced isomerization, since more than 80% of the trans-RES in solution is con-
verted to cis-RES if exposed to light for 1h (Vian, et al., 2005). 
Trans-RES has effects on many metabolic processes and has been suggested to modulate 
cardiovascular disease, inflammation, cancer, obesity, diabetes, and neurodegenerative dis-
eases (Giovinazzo, et al., 2012) (Patel, et al., 2011). Some authors have affirmed that RES 
displays wide pharmacological activities such as antioxidant, anti-inflammatory, 
anticarcinogenic, analgesic, cardioprotective, chemo-preventive, anti-aging activities and 
neuroprotective (Baur & Sinclair, 2006) in some neurological disorders, such as AD, PD, HD, 
brain ischemia and epilepsy (Gusman, et al., 2001). Many studies confirm that RES acts in CNS. 
RES can pass through the BBB (Baur & Sinclair, 2006) and induce protective effects in neuro-
degenerative diseases such as cerebral ischemia (Gao, et al., 2006), AD (Marambaud, et al., 
2005) and PD (Okawara, et al., 2007). 
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         a)                                                                       b) 
 
Figure 2.6 - Chemical structures of resveratrol isomers. a) cis-RES, and b) trans-RES. 
 
 RES has low bioavailability, resulting from its low solubility in water (less than 0,05 
mg/ml) (Amri, et al., 2012) (Walle, 2011). The low bioavailability and rapid clearance from 
the circulation of RES make difficult to establish bio efficacious concentrations of RES in the 
blood and tissues of humans. RES can be dissolved in various common organic solvents, such 
as ether, ethanol, methanol, dimethyl sulfoxide (DMSO), but hardly dissolved in water (Walle, 
2011).  
 RES has several disadvantageous properties that justify its encapsulation in carriers, such 
as: poor water solubility, short biological half-life, chemical instability and its rapid metabo-
lism and elimination (Nicolás, et al., 2006). 
 Through the encapsulation is possible to increase the RES solubility in water and thereby 
also improve its bioavailability. Encapsulation may be used to stabilize RES against degrada-
tion (Amri, et al., 2012). The carrier aims to increase the therapeutic potential of RES, pre-
venting their degradation and simultaneously cause side effects elsewhere in the body (Kristl, 
et al., 2009) (Mufamadi, et al., 2010). 
 
2.3.1 –Effect of Resveratrol on Alzheimer's Disease 
Several data support the role of oxidative stress in neurodegenerative diseases including 
AD and consequently support the beneficial effect of antioxidant as therapy of these diseases 
(Li, et al., 2006) (Robb, et al., 2008) (Sun, et al., 2010). Oxidative stress induces neuronal 
damages and modulates intracellular signaling, leading to neuronal death by apoptosis or ne-
crosis (Li, et al., 2012). Various clinical studies indicate that antioxidants may delay the ap-
pearance of neurodegenerative diseases (Engelhart, et al., 2002) (Morris, et al., 2002). Natu-
ral compounds such as RES and other herbs have a variety of functions becoming candidates 
for a new generation of drugs for the treatment of patients with AD (Anekonda & Reddy, 
2005) (Howes & Houghton, 2003). 
 In vitro studies suggest that RES may protect against oxidative damage induced by Aβ 
(Conte, et al., 2003) (Jang & Surh, 2003) (Kim, et al., 2007), and may encourage Aβ clearance 
through promotion of intracellular proteosomal activity (Marambaud, et al., 2005) (Saiko, et 
al., 2008). 
 Human sirtuins are coded by seven different genes (SIRT1 to SIRT7), whose their functions 
are still being investigated (Haigis & Guarente, 2006) (Michan & Sinclair, 2007). Sirtuins are 
located in different tissue types and they are classified into four classes of proteins: SIRT1–3 
(class I), SIRT4 (class II), SIRT5 (class III), and SIRT6–7 (class IV) (Frye, 2000) (Shi, et al., 2005). 
SIRT1, SIRT6, and SIRT7 are localized in nucleus, with SIRT6 localized specifically in hetero-
chromatic regions and SIRT7 in nucleoli (Michishita, et al., 2005). SIRT2 is localized in cyto-
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plasm, and SIRT3, SIRT4, and SIRT5, in mitochondria (Frye, 2000) (Michishita, et al., 2005) 
(Shi, et al., 2005). SIRT1 appears to have a role in the basic processes related to mammal se-
nescence such as food and glucose metabolism, adipose tissue homeostasis or DNA repair 
(Rodgers & Puigserver, 2007) (Qiang, et al., 2007) (Wang, et al., 2006). RES has been inten-
sively investigated as an enzyme activator of SIRT1 (Chen, et al., 2005) (Kim, et al., 2007) 
(Parker, et al., 2005) (Qin, et al., 2006). RES is capable of binding to the N-terminal of SIRT1 
increasing their activity (Milne & Denu, 2008). In the model of AD, the direct introduction of 
RES in the cerebral ventricles reduces neuronal death in the hippocampus, avoids learning 
difficulties and reduces the acetylation of the known SIRT1 substrates PGC-1   and p53 
(Anekonda, 2006) (Karuppagounder, et al., 2009) (Kim, et al., 2007). SIRT1 activation or 
overexpression was reported as neuroprotective in models of AD, by a still unknown mecha-
nism (Chen, et al., 2005) (Kim, et al., 2007) (Parker, et al., 2005) (Qin, et al., 2006). 
 Studies suggest that RES can prevent Aβ42 toxicity by direct interaction with Aβ42 fibrils 
due to the fact that RES destabilizes the Aβ42 fibrils and delays oligomers and fibrils formation 
of Aβ42 (Ahn, et al., 2007) (Albani, et al., 2009) (Feng, et al., 2009) (Jang, et al., 2007) 
(Rivière, et al., 2007). This property of reducing the Aβ toxicity seems to be a general feature 
of polyphenols (Albani, et al., 2010) (Feng, et al., 2009) (Ono, et al., 2008). In addition, RES 
reduces the Aβ levels by promoting a non-amyloidogenic processing of APP and promoting 
clearance of intracellular Aβ via the proteasomes (Li, et al., 2012) (Marambaud, et al., 2005). 
There is clear evidence that a decrease in proteasome activity occurs in AD brains (Keller, et 
al., 2000) (Salon, et al., 2000). Studies propose that Aβ can lead to inhibition of proteasome, 
suggesting that high levels of Aβ in AD brain can create a vicious cycle by inhibiting the pro-
teasome and blocking the degradation of critical regulators of its own clearance (Marambaud, 
et al., 2005) (Saiko, et al., 2008). 
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Chapter 3 
 
 
Characterization of Resveratrol 
 
 
 
Trans-resveratrol (RES) is a natural nonflavonoid poly-phenolic compound present in over 
than 70 species of plants including vegetables, fruits, grains, roots, flowers, seeds, tea and 
wine (Amri, et al., 2012) (Chachay, et al., 2011). Chemically, RES has two geometrical iso-
mers (Figure 2.9), trans-RES and cis-RES, with the trans form as the biologically active form 
(Filip, et al., 2013). RES is a highly photosensitive compound susceptible to UV-induced isom-
erization, since more than 80% of the trans-RES in solution is converted to cis-RES if exposed 
to light for 1h (Vian, et al., 2005). 
 RES has interesting biochemical and physiological properties such as antioxidant, anti-
inflammatory, anticarcinogenic, analgesic, cardioprotective, chemo-preventive, anti-aging 
activities and neuroprotective (Ahn, et al., 2007) (Baur & Sinclair, 2006) (Gusman, et al., 
2001). Many studies confirm that RES acts in CNS. RES can pass through the BBB (Baur & Sin-
clair, 2006) and induce protective effects in neurodegenerative diseases such as cerebral is-
chemia (Gao, et al., 2006), AD (Marambaud, et al., 2005) and PD (Okawara, et al., 2007). RES 
has anti-amyloidogenic activity because it promotes the intracellular degradation of Aβ by a 
mechanism involving the proteasome, thereby reducing levels of Aβ (Marambaud, et al., 
2005). 
 RES has several disadvantageous properties that justify its encapsulation in carriers, such 
as: poor water solubility, short biological half-life, chemical instability and its rapid metabo-
lism and elimination (Nicolás, et al., 2006). Through the encapsulation is possible to increase 
the RES solubility in water and thereby also improve its bioavailability. Encapsulation may be 
used to stabilize RES against degradation (Amri, et al., 2012) and increase the therapeutic 
potential of RES (Kristl, et al., 2009) (Mufamadi, et al., 2010). 
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3.1 – Material and Methods 
 
3.1.1 –Resveratrol’s Solutions 
Trans-resveratrol (C14H12O3 or 3, 5, 4’-trihydroxystilbene, purity ≥ 99%, molecular weight 
(MW) 228.24) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Extracts of the grape 
seed and grape skin (purity ≥ 95%) was purchased from Monteloeder (Elche, Alicante, Spain). 
Stock solutions were prepared by dissolving RES, grape seed extract and grape skin extract in 
phosphate buffered saline (PBS), pH 7.4 (PBS, 10 mM phosphate buffer, 2.7 mM potassium 
chloride and 137 mM sodium chloride, Sigma-Aldrich). The buffer was prepared previously 
with ultrapure water purified with Mili-Q equipment with the specific resistance of 18.2 
MΩ·cm (Milli-Q Academic, Millipore, France). To ensure complete dissolution, the three solu-
tions were placed in the bath at 70°C for 10 minutes (Thermo Scientific Haake DC10-P5/U 
Heating Circulator Baths, Termo Fisher Scientific, USA). Solutions of the extracts of the grape 
seed and grape skin were exposed to centrifugal force under 14 000 rpm for 15 minutes 
(MiniSpin plus, eppendorf, Germany) and the supernatant used. 
To produce a linear calibration curve of RES dissolved in PBS, solutions were prepared at 0, 
5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70 and 80 μM. The absorbance of the samples at wave-
length 305 nm was measured using BioTek® Synergy 2 Multi-Mode Reader (Winooski, Vermont, 
USA) and UV-1700 PharmaSpec UV-VIS Spectrophotometer Shimadzu (Kyoto, Japan).  
  
3.1.2 –Ultraviolet Spectrophotometry 
Radiation spectrophotometry in the ultraviolet (UV) region is widely used for qualitative 
or quantitative analysis due to its accuracy and, therefore, useful in several areas such as 
chemistry, physics, biochemistry, engineering materials, among others (Rocha & Teixeira, 
2004). 
The spectrophotometry is a method to measure the amount of light that absorbs a chemi-
cal substance through measurement of light intensity of a light beam that passes through a 
given solution. When a solution with absorbent molecules is crossed by a beam of monochro-
matic light of this light is absorbed by the solution and the rest is transmitted. Light absorp-
tion is also influenced by the concentration of the absorbing molecules (El-Kabbany, et al., 
2014). 
It can also be used to measure the concentration of a chemical known in an easy, practi-
cal and fast way. Therefore, spectrophotometry studies the interaction of electromagnetic 
radiation with matter (El-Kabbany, et al., 2014) (Rocha & Teixeira, 2004). 
The instrument used in UV spectrophotometry is the spectrophotometer. A transparent 
cell which does not absorb radiation in the wavelength range used (the wavelength range of 
UV radiation is considered to be between 200 and 400 nm), commonly called cuvette is filled 
with the liquid sample and placed in the spectrophotometer. To get information about the 
absorbance of a sample it is inserted in the optical path of the apparatus where UV light 
passes through the sample which enables the spectrophotometer to measure the amount of 
light that is absorbed (El-Kabbany, et al., 2014) (Rocha & Teixeira, 2004). 
The interaction of UV radiation with matter can provides information about substances by 
the analysis of the UV spectrum. This spectrum is a graphical representation of the relation-
ship of the absorption of the radiation, by the substance in study, as a function of the radia-
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transmitted light 
(I) 
Intensity of 
incident light 
(I0) 
tion wavelength. The analysis of this spectrum allows concluding the range of wavelength 
that the substance has a greater tendency to absorb UV radiation (Rocha & Teixeira, 2004). 
A common spectrophotometer has in its constitution a radiation source and a detector. 
The radiation source focuses a light beam which travels through a path reaching the sample. 
In the sample part of the radiation is absorbed, and only some of it transmitted through the 
sample reaching the detector. Thus, the amount of absorbed radiation is determined by the 
difference between the incident light (I0) and the light which effectively reaches the detector 
(I) (Figure 3.1). This relationship is translated by the equation 3.1 (El-Kabbany, et al., 2014): 
 
          
 
  
  ,                                                    (3.1)                                                  
where A is the absorbance; I, the light that was through the sample and reached the detec-
tor; and I0, the incident light.   
 
 
 
Figure 3.1 - Schematic representation of the basic principle of UV spectrophotometry. 
 
Quantification of substances by spectrophotometry is based on the Lambert-Beer law 
(Equation 3.2). This law is the mathematical basis for the measurement of radiation absorp-
tion by the sample in UV regions of the electromagnetic spectrum.  
 
         ,                                                          (3.2) 
where A is the absorbance; ε, the molar absorptivity; c, the sample concentration; and l, the 
path length (El-Kabbany, et al., 2014).  
Some aspects have to be taken in consideration, in order to obtain a consolidated analysis. 
The solute must be dissolved in a solvent and the solvent must be transparent over the wave-
length range of interest. Therefore, the choice of the solvent must be done carefully since it 
may affect the appearance of the spectrum as they can shift the position of the absorption 
band. Also, if the solute isn’t dissolved completely, undissolved particles can scatter light 
from the light source. Particles aggregates may also distort the results since as the distance 
between molecules become smaller the charge distribution will be affected which alter the 
molecules ability to absorb a specific wavelength. All this can result in errors in the analyses 
(Rocha & Teixeira, 2004). 
 
 
 
 
 
Detector Monochromator 
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3.2 – Results and Discussion 
 
3.2.1 –Calibration Curve 
To produce a linear calibration curve of RES dissolved in PBS, solutions with concentra-
tions known were prepared and the absorbance of the samples at wavelength 305 nm was 
measured using BioTek® Synergy 2 Multi-Mode Reader (Winooski, Vermont, USA) and UV-1700 
PharmaSpec UV-VIS Spectrophotometer Shimadzu (Kyoto, Japan) and two calibration curves 
were obtained (Appendix 1 and Appendix 2, respectively). 
The results of calibration curves demonstrate that the calibration curves obtained have 
excellent linear relationship between concentration and absorbance, which translates into a 
coefficient of determination (R2) of 0.995. It can be concluded also that the calibration curves 
have different sensitivities, result of the different sensitivities of the equipment used.  
 
3.2.2 –Resveratrol’s percentage in extracts 
The percentage of RES presented in the two extracts were determined in three solutions 
were prepared in PBS, one solution containing RES, another with grape seed extract, and an-
other grape skin extract, all at a concentration of 18.26 μg/ml. The absorbencies of the sam-
ples were read at a wavelength of 305 nm using BioTek® Synergy 2 Multi-Mode reader (Winoo-
ski, Vermont, USA) and were converted to concentrations through the RES calibration curve. 
Determined the concentrations of the samples, the percentages of RES contained in the two 
extracts were calculated. The concentrations obtained were 4.72% and 3.81% of the RES in 
the seed extract and in the grape skin extract, respectively.  
Iacopini, et al. used HPLC–UV to quantify the amount of RES in seed and skin of the grape.  
The authors studied the total RES content in ten grape varieties. In all varieties, only a very 
small concentration of RES was detected, ranging between 0.670 ± 0.16 and 25.57 ± 1.16 
mg/100g of seeds and skins extracts, depending of the grape varieties (Iacopini, et al., 2008). 
This values account for about 0.00067 and 0.02557% of RES present in extracts. Sun et al. 
quantified the amount of RES by HPLC in seed and skin of the grape and reported that the 
levels of RES were extremely low, around 6.8 mg/kg (Sun, et al., 2006) which is equivalent to 
approximately 0.00068%. 
The difference between the published literature and this work were significantly differ-
ent. These differences can be explained by the fact that the large amount of different flavo-
noids is present in skin and seeds grape. Given that the absorbance of flavonoids is maximum 
in the region of 304-350 nm (Santos, et al., s.d.), the absorbance obtained at a wavelength of 
305 nm may not be due only to the RES. 
 
3.2.3 – Stability Studies 
The stability of RES and seed and skin grape extracts was analyzed at different tempera-
tures and pHs. 
 
3.2.3.1 – Stability Study with Temperature 
To study the stability of the RES and the extracts, depending on the temperature, solu-
tions were prepared in PBS at a concentration of 80 μM and stored at 4 °C, 25 °C (room tem-
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perature) and 37 °C (physiological body temperature) for a period of two weeks.  Every days, 
the UV-spectrum of the samples was measured. Regardless of the storage temperature of the 
samples it was found that the maximum absorbance of RES always occurs at a wavelength of 
305 nm. 
The results of stability studies with temperature (Figure 3.2 a) demonstrated that RES is 
stable when stored at 4 °C. The absorbance at 4 ºC doesn’t show statistically significant dif-
ferences (P<0.050) along the days. At 23 and 37 °C, the absorbance of RES at 305 nm de-
creases around 44% and 63%, in 7th day and 60% and 76%, in 14th day, respectively, which sug-
gests that the temperature increase promotes the degradation of the RES. Thus, the degrada-
tion process of RES exhibits sensitivity to temperature. Therefore, at 37 °C degradation was 
fast, whereas the storage at 4 °C slowed the reaction by the decreased molecular mobility. 
Relative to the extracts the results demonstrated that the absorbance of the samples at 305 
nm doesn’t show the statistically significant differences (P<0.050) along the days inde-
pendently of temperature used in the solution store (Figure 3.2 b) and c)). This suggests that 
the extracts are stable for a period of 14 days at 4, 23 and 37 °C.  
The impact of temperature on RES stability was studied at different temperatures is re-
ferred in literature.  Zupančič, et al. prepared solutions of RES in buffers with pH 7.4 and 
stored at −22, 4, 25, and 37 °C for three months. The authors demonstrated that at pH 7.4 
RES rapidly degraded at 25 and 37 °C, whereas the degradation was slowed at 4 °C and pre-
vented at −22 °C (Zupančič, et al., 2015). Thus, RES stability can be increased with lower 
temperatures, as our findings confirmed. Liazid, et al. showed that when RES was exposed for 
20 minutes to increased temperatures the extent of degradation is 17% at 125 ºC, 39% at 150 
ºC, and 70% at 175 °C (Liazid, et al., 2007).  
 
3.2.3.2 – Stability Study with pH 
To study the stability of RES and extracts depending on the pH, RES solutions were pre-
pared in PBS at a concentration of 80 μM and extract solutions at a concentration of 85 μg/ml. 
Five different pH values were used: 4, 5, 7.4, 8 and 11. The samples were stored at 4 °C and 
the UV-spectrums were measured in the wavelength range of 200 to 400 nm, for a period of 7 
days.  
The results of stability studies with pH (Figure 3.3) demonstrated that RES (Figure 3.3 a)) 
is stable at pH values below 7.4. At pH 8, the absorbance values slightly decreased but the 
peak of maximum absorption remains at 305 nm. At pH 10, the absorbance of RES decreased 
significantly and the peak of maximum absorption changed to 318 nm. Thus, these results 
suggest that RES is stable only for acidic pHs and neutral pH whereas basic pHs promote their 
degradation. Relative to the Figure 3.3 b) and c), the results demonstrated that the extracts 
aren’t stable only for pH 10. In this case the peak of maximum absorption suffered a detour 
and the absorbance of extracts increased lightly. Over the 7 days, at pH acid, UV-spectrum of 
the RES and extract didn’t change while with basic pH was found to degradation of the RES 
and extracts even when stored at 4 °C. 
The effect of pH on RES stability has been investigated in a study of Trela & Waterhouse 
showing that RES is stable in buffers with pH 1, 3.5, and 7.0 for 28 days, whereas at pH 10 it 
rapidly degraded with a half-life of only 1.6 hours (Trela & Waterhouse, 1996). Zupančič, et 
al. prepared solutions of RES in buffers with pH 1.2, 6.8, 7.4, 8, 9 and 10 and stored at 4 °C 
for three months. RES was relatively stable in acidic conditions, whereas its degradation rate 
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exponentially increases in alkaline ones. The authors suggest that RES was stable in acidic pH 
because its hydroxyl groups were protected from radical oxidation by positively charged H3O
+ 
(Zupančič, et al., 2015).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 – Absorbance at a wavelength of 305 nm of a) RES, b) skin grape extract and c) seed grape 
extract. The samples were stored at 37°C, 23ºC and 4ºC for 14 days (n=3). 
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Figure 3.3 – UV-spectrum of a) RES, b) grape skin extract and c) grape seed extract, at pH values of 4, 5, 
7.4, 8 and 10. These results are relative to the first day. 
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Chapter 4 
 
 
Nanocarriers Preparation and Character-
ization 
 
 
 
Many advantages of NP-based drug delivery have been recognized. The NPs improves the 
bio-availability by enhancing aqueous solubility, increases resistance time in the body (in-
creasing half life of drug systemic circulation for clearance), releases drugs at a sustained 
rate and thus lowers the frequency of administration and target the drug to specific location 
in the body (its site of action) (Mudshinge, et al., 2011) (Zhang, et al., 2008). 
A growing effort has being applied to find novel approaches for neurodegenerative treat-
ment and in recent years a growing number of studies, focused on the research and develop-
ment of nanoparticles as drug delivery systems, have been conducted (Wilczewska, et al., 
2012). Liposomes and PLGA have different physico chemical, biochemical and mechanical 
properties each presenting their own advantages where drug delivery is concerned. As the 
success of a neurodegenerative disease therapy depends not only on the pharmacokinetic and 
pharmacodynamic activity of the therapeutic agent, but to a large extent, on its bioavailabil-
ity and toxicity (Acharya & Sahoo, 2011), the development of a nanocarrier for RES will allow 
to enhance its therapeutic activity. 
 
 
4.1 – Material and Methods 
 
4.1.1 –Liposomes Preparation 
Hydration of a thin lipid film is the original method initially used for liposomes production 
(Laouini, et al., 2012). This method continue to be the most common and simple method for 
preparation of MLVs (Popovska, et al., 2013) (Sirisha, et al., 2012). The lipids must first be 
dissolved and mixed in an organic solvent to assure a homogeneous mixture of lipids. Usually 
this process is carried out using chloroform (CF), dichloromethane, ethanol or a mixture of 
chloroform and methanol. Then, the organic solvent was removed by evaporation to yield a 
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Lipids in organic 
solvent 
MLVs SUVs 
lipid film. For small volumes of organic solvent, the solvent may be evaporated using dry ni-
trogen in a fume hood. For larger volumes, the organic solvent should be removed by rotary 
evaporation yielding a thin lipid film on the sides of a round bottom flask. To remove residual 
organic solvent the thin lipid film is placed on a vacuum pump overnight (Dua, et al., 2012). 
Finally, the dry lipidic film deposited on the flask wall is hydrated by adding an aqueous buff-
er solution under agitation at temperature above the phase transition temperature of lipid 
(Tm) (Laouini, et al., 2012) (Popovska, et al., 2013) (Sirisha, et al., 2012). When hydrated, 
phospholipids spontaneously assemble into liposomes due to their amphiphilic nature. They 
tend to assemble in vesicles in order to decrease the system free energy, by decreasing the 
water contact of phospholipids hydrophobic tails (Dua, et al., 2012). Depending upon their 
solubilities the compounds to be encapsulated can be added either to aqueous buffer or to 
organic solvent containing lipids (Sirisha, et al., 2012). The dispersed phospholipids in aque-
ous buffer yield a population of MLVs heterogeneous both in size and shape. Thus, liposome 
size reduction techniques, such as sonication for SUVs formation or extrusion through poly-
carbonate filters forming SUVs are useful to produce a population with size of vesicles more 
uniform (Dua, et al., 2012)  (Laouini, et al., 2012) (Popovska, et al., 2013). The figure 4.1 
shows this method step-by-step. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 – Liposome production steps by method of hydration of a thin lipid film. Adapted from (Lasic, 
1997). 
 
Sonication is perhaps the most broadly used method for the preparation of SUVs 
(Akbarzadeh, et al., 2013). This method consist in disruption of MLVs suspensions using sonic 
energy (sonication) typically produces SUVs. The sonication of MLVs dispersion is accom-
plished by placing a test tube containing the suspension in a bath sonicator or placing the tip 
Evaporation of 
solvent 
 
Lipid film Addition of aqueous solution 
 
Hydration with agitation 
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of the sonicator in the test tube for 5 to 10 minutes above the Tm of the lipid (Dua, et al., 
2012) (Sirisha, et al., 2012). 
Lipid extrusion is a technique in which a lipid suspension is forced to pass through a poly-
carbonate filter with a defined pore size to yield particles having a diameter smaller, near 
the pore size of filter used (Lasic, 1997) (Sirisha, et al., 2012). 
After the hydration is common perform the method of freezing and thawing of liposomes 
for increasing the trapped volume of drug. The freeze-thaw method is dependent on the ionic 
strength of the medium and the phospholipid concentration. It induces the physical disruption 
of lamellar structure leading to formation of LUVs. In general, the freeze and thawing cycles 
are repeated thirteen times (Akbarzadeh, et al., 2013) (Sirisha, et al., 2012). 
For the production of liposomes, all the lipids were purchased from Avanti Polar Lipids 
(Alabama, USA): DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine, MW 790.145), Chol (cho-
lesterol ovine wool, MW 386.66), DSPE-PEG2000 (1,2- distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (ammonium salt), MW 2790.49), 
POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, MW 760.10) and DOTAP (1,2-
dioleoyl-3-trimethylammonium-propane (chloride salt), MW 698.55). The chemical structure 
of the phospholipids is shown in table 4.1. Trans-resveratrol (3,5,4’-trihydroxystilbene, purity 
≥ 99%, MW 228.24) was purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Several approaches were used in order to encapsulate RES. All liposomes were prepared 
by the classic method of the lipid film hydration (Lasic, 1997). In the first approach, DSPC, 
Chol and DSPE-PEG2000 were dissolved in chloroform (CF, MW 119.38, Sigma-Aldrich), at the 
molar ratio of 52:45:3. A lipid film was formed by evaporating the solvent through manual 
rotation under a nitrogen atmosphere. The nitrogen atmosphere allows rapid solvent evapora-
tion and inhibits lipids oxidation. The film was held in a desiccant container overnight, to ac-
complish chloroform complete evaporation. The resultant dried lipid film was hydrated with 
1.5 mL of a solution of RES in PBS buffer 7.4 (phosphate buffered saline, 10 Mm phosphate 
buffer, 2.7 mM potassium chloride and 137 mM sodium chloride, Sigma-Aldrich) at a molar 
ratio of 1:10 (RES: lipids moisture). The final lipid concentration was 0.8 mM and the RES con-
centration was 80 μM. After the lipid film was peeled off completely through vigorous shaking 
in a vortex (Vortex Genius 3, Ika®, Germany) for 15 minutes, to yield MLVs. In order to obtain 
LUVs, the suspension was submitted to ultrasounds in a sonicator bath (Ultrasonic cleaner, 
VWR®, Malasya) for 10 minutes, followed by extrusion through a polycarbonate membranes 
(Nuclepore Track-Etch Membrane, Whatman®, Maidstone, UK) with a specific pore size 11 
times using an extruder (Mini-extruder, Avanti® Polar Lipids, Alabama, USA). The liposomes 
were then sequentially passed through membranes with pore diameters of 200 and 100 nm.  
Table 4.2 shows the summary of the various approximations performed. 
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Table 4.1 - Chemical structure of the lipids used to prepared liposomes. 
 
Chemical Structure Names 
 
DSPC: 1,2-distearoyl-sn-
glycero-3-
phosphocholine 
 
DSPE-PEG2000: 1,2- 
distearoyl-sn-glycero-3-
phosphoethanolamine-
N-[amino(polyethylene 
glycol)-2000] 
 
POPC: 1-palmitoyl-2-
oleoyl-sn-glycero-3-
phosphocholine 
 
DOTAP: 1,2-dioleoyl-3-
trimethylammonium-
propane 
 
 
 
 
 
 
Cholesterol 
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Table 4.2 - Summary of the several approaches performed for production of liposomes. 
 
Approaches 
1 2 3 4 5 6 7 8 9 10 11 
12 
Lipids 
DSCP ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ 
✕ 
Chol ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
✓ 
PEG ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ 
✕ 
POPC ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✓ 
✕ 
DOTAP ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✓ ✕ 
✓ 
Molar ratio 
(lipid:Chol:PEG) 
52:45:3 52:45:3 52:45:3 52:45:3 52:45:3 52:45:3 52:45:3 52:45:3 55:45 55:45 10:1 
10:1 
Organic 
solvent 
CF CF CF CF CF CF CF CF EtOH EtOH EtOH 
EtOH 
Molar ratio 
(RES: lipids moisture) 
1:10 1:20 1:100 1:10 1:10 1:10 1:10 1:10 1:4 1:4 1:4 
1:4 
Final lipid concentra-
tion 
0.8 mM 1.6 mM 8 mM 0.8 mM 0.8 mM 0.8 mM 0.8 mM 0.8 mM 80 mM 80 mM 80 mM 
80 mM 
RES concentration 80 μM 80 μM 80 μM 80 μM 80 μM 80 μM 80 μM 80 μM 20 mM 20 mM 20 mM 
20 mM 
Addition 
of RES 
Organic 
phase 
✕ ✕ ✕ ✓ ✓ ✕ ✕ ✕ ✓ ✓ ✓ 
✓ 
Aqueous 
phase 
✓ ✓ ✓ ✕ ✕ ✓ ✓ ✓ ✕ ✕ ✕ 
✕ 
drug solution  sol-
vent 
PBS PBS PBS CF EtOH 
10% (v/v) 
DMSO in  
water 
2% (v/v) 
EtOH in  
water 
water EtOH EtOH EtOH 
 
EtOH 
Freezing/unfreezing 
cycles 
✕ ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✓ ✓ 
✓ 
Extrusion ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ 
✕ 
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4.1.2 –PLGA Nanoparticles Preparation 
Several methods have been devised to synthesize PLGA NPs depending on the physic-
chemical characteristics of the drug to be encapsulated. The characteristics of the obtained 
NPs, as size and structural organization, depend upon the chosen method and solvents 
(Kumari, et al., 2010) (Makadia & Siegel, 2011). The most common methods are single or dou-
ble-emulsion solvent evaporation and nanoprecipitation (Kumari, et al., 2010). While 
nanoprecipitation is suitable for the entrapment of both hydrophobic and hydrophilic drugs 
(Schubert, et al., 2011), the choice of single or double emulsion depends upon the 
hydrophilicity of the drug to be encapsulated (Makadia & Siegel, 2011). Single-emulsion is a 
suitable choice for encapsulating hydrophobic drugs, and double-emulsion is mostly used for 
hydrophilic drugs (Danhier, et al., 2012) (Makadia & Siegel, 2011).  
The technique used in this work was the emulsification-solvent evaporation technique. 
This process involves oil-in-water (o/w) emulsification. Polymer in the appropriate amount is 
first dissolved in a water immiscible, volatile organic solvent in order to prepare a single 
phase solution. The drug is then added to the polymer solution to produce a solution or dis-
persion of the drug particles. This polymer dissolved drug dispersed solution is then emulsi-
fied in a larger volume of water in presence of an emulsifier to yield an o/w emulsion. The 
emulsion is then subjected to solvent removal by either evaporation or extraction process to 
harden the oil droplets. The solid microspheres so obtained are then washed and collected by 
filtration, sieving, or centrifugation (Hans & Lowman, 2002) (Jain, 2000) (Makadia & Siegel, 
2011) (Vasir & Labhasetwar, 2007) (Wischke & Schwendeman, 2008). 
For PLGA NPs preparations, PLGA Resomer® RG503H (50:50; MW 24.000 – 38.000), trans-
resveratrol (purity ≥ 99%, MW 228.24), ethyl acetate (MW 88.11), acetone (MW 58.08) and 
Pluronic® F-127 were purchased from Sigma–Aldrich (St. Louis, Mo., U.S.A). Extracts of the 
grape seed and grape skin (purity ≥ 95%) was purchased from Monteloeder (Elche, Alicante, 
Spain). Two aqueous solutions of 0.1% and 1% (w/v) Pluronic F-127 were prepared in deion-
ized and filtered ultrapure Milli-Q water (Milli-Q Academic, Millipore, France). 
To synthesize PLGA NPs, two experimental conditions were tested. In the first experi-
mental condition, 100 μl solution of 100 mg/ml of PLGA in ethyl acetate was prepared and 
RES (36.52 μg), extracts of grape seed (0.77 mg) and skin (0.96 mg) were added. In the se-
cond experimental condition, the drugs were dissolved in 50 μl of acetone and added at 100 
μl solution of 100 mg/ml of PLGA in ethyl acetate. Then, 200 μL of an aqueous solution of 1% 
(w/v) pluronic F-127 was added dropwise to the organic phase. The moisture was vortexed 
(Genius 3, ika®vortex, Germany) for 30 seconds and emulsified by sonication for 5 minutes in 
a beaker with ice using Ultrasonic cleaner (VWRTM, Malaysia). Typically, stirring of the emul-
sion originates microdroplets. In order to induce the nanosized droplets, sonication process 
was carried out. The size reduction is induced through a two-step mechanism. Firstly, apply-
ing acoustic waves through the water creates interfacial waves and instability, which causes 
the eruption of the oil phase into the water medium in the form of droplets. Secondly, apply-
ing low frequency ultrasound causes acoustic cavitation, that is, the formation and subse-
quent collapse of microbubbles, leading to turbulence. This turbulence breaks up the primary 
droplets of dispersed oil into nanosized droplets (Jafari, et al., 2006) (Kentish, et al., 2008). 
After emulsification completed, the emulsion was poured rapidly into 2.5 ml of 0.1% (w/v) 
pluronic F-127 and stirred (800 rpm) at 70ºC for 10 minutes in order to completely evaporate 
the organic solvent and ensure complete dissolution of the drugs, using MR 3001 K series mag-
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netic stirring hotplate (Heidolph, Germany). The evaporation step was performed in a flow 
chamber SterilGARD® e3 from The Baker Company (Sanford, USA). It is important to note that, 
this transfer step must be completed very quickly, in order to avoid PLGA NPs aggregation 
before being stabilized by the surfactant (Li, et al., 2008). 
The resulting suspension was filtered with Millex-GP Filter Units (0.2 μm, 
polyethersulfone) (Millipore Express, Ireland) and incubated at 4ºC overnight to avoid NPs ag-
gregation and increase their stability. Then the NPs were collected by centrifugation (14500 
rpm for 30 minutes) with MiniSpin®plus (Eppendorf, Germany), and the pellet was re-
suspended in ultrapure water and stored for analysis. 
 
4.1.3 – Encapsulation Efficiency of Liposomes 
  The first step for the determination of the encapsulation efficiency is the separation be-
tween the encapsulated and free drug. Several separation techniques have been described in 
the literature (Laouini, et al., 2012) (Popovska, et al., 2013) (Vanaja, et al., 2013). Free RES 
was removed from liposome dispersions by two techniques, dialysis and gel-permeation chro-
matography. 
In the first technique, the separation between the free RES and the encapsulated RES was 
performed using a dialysis membrane with an approximate molecular weight cut-off (MWCO) 
of 100 kDa (Spectra/Por® Float-A-Lyzer® G2, Spectrum Laboratories, USA). Initially, the mem-
brane was submerged overnight in ultra-pure water to remove glycerin and achieve maximum 
permeability. Then, 500 μl of sample was placed into dialysis bag. The liposomal suspension 
was dialysed against 6 ml of PBS for 2h30 at 4ºC. The medium of dialysis was replaced every 5 
minutes. 
 To study the efficiency of encapsulation using the second technique, PD MiniTrapTM G-25 
column contain SephadexTM G-25 Medium (GE Healthcare, Uppsala, Sweden) was used to sepa-
rate free RES from liposomes. Free RES and liposomes were separated through gravity proto-
col based on their different sizes. As liposomes are larger than the pores of column, they are 
excluded and therefore eluted. Unloaded liposomes suspension and solution of RES were also 
submitted to this separation process as a control. Depending on the hydration solution used in 
preparation of the liposomes the column was equilibrated with 8 ml of ultra-pure water or 
PBS and then 0.5 ml of liposomes suspension was added to the column.  As the sample en-
tered the packed bed completely, it was eluted and collected with 1.0 ml of PBS. 
 After the separation, to quantify the amount of RES encapsulated, the liposomes were 
burst with sodium dodecyl sulphate (SDS, MW 288.38, Sigma-Aldrich, Germany), in a 25:75 
(v/v) proportion (liposomes: SDS) and their absorbance was measured using BioTek® Synergy 2 
Multi-Mode Reader. 
 The encapsulation efficiency (EE%) is defined as the ratio between the amount of resvera-
trol encapsulated in liposomes and the amount of resveratrol used for the preparation follow-
ing equation (Isailović, et al., 2013) (Lu, et al., 2012):  
 
  EE% = 
                           
                   
 x 100.                                (4.1)  
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4.1.4 – Encapsulation Efficiency, Loading Capacity and Process Yield of PLGA 
NPs 
To quantify the amount of RES and seed and skin grape extracts encapsulated in the NPs, 
the NPs suspensions were centrifuged (14500 rpm for 30 minutes) and the supernatants ana-
lyzed. The samples were measured by UV-Vis spectrophotometry at 305 nm, using a UV-1700 
PharmaSpec UV-VIS Spectrophotometer Shimadzu (Japan). The results were correlated to cal-
ibration curve (Figure 3.3). Encapsulation efficiency (EE%) of PLGA NPs was calculated by the 
following equation: 
 
EE% = 
                                          
                   
 x 100.                      (4.2) 
 
 
RES, seed and skin grape extracts loading capacity (LC%) of PLGA NPs was calculated by 
the following equation: 
 
LC% = 
                                          
                      
 x 100.                      (4.3) 
 
 
The process yield (PY%) of NPs was calculated by comparing the quantity of polymer and 
drug initially taken for the production process, and the quantity of the NPs finally obtained. 
The yield of the process was calculated by the following equation: 
 
 
PY% = 
                         
                                            
 x 100.                      (4.4) 
 
To determine the NPs weight, the NPs suspension was centrifuged (14500 rpm for 30 
minutes). The pellet NPs were resuspended in 200 μl of deionized water and the supernatant 
was discarded. The pellet was dried overnight, and the final mass of the NPs was measured. 
 
 4.1.5 – Stability Studies 
 In order to evaluate the PLGA NPs stability, PLGA NPs’ dispersions in ultrapure water were 
stored at 4 °C. These tests were performed in all formulations prepared (unloaded-PLGA NPs, 
RES-loaded, grape seed extract-loaded and grape skin extract-loaded NPs, for the two exper-
imental conditions). The stability of the PLGA NPs was analyzed through the size and zeta 
potential variation. These measurements were performed every day, over a period of 1 month.  
 The size was measured by dynamic light scattering (DLS) technique at RT. Zeta potential 
was also measured for the same samples by the laser Doppler velocimetry method. The meas-
urements were performed in a ZetaSizer Nano ZS (Malvern instrument, Worcesterchire, UK). 
 
4.1.5.1 – Zeta Potential 
The overall charge that a particle acquires in a particular medium is called zeta potential. 
Any particle in suspension exhibits this physical property. Measurements of zeta potential are 
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commonly used to study the stability of colloidal systems. If the particles in suspension have a 
large zeta potential (negative or positive) they will tend to repel each other and there will be 
no tendency to aggregation. However, if the particles have low zeta potential values there 
will be no force to prevent the particles flocculating. To measure the zeta potential, the par-
ticles are illuminated by a laser that provides a light source. When an electric field is applied 
to the cell, any particles moving through the measurement volume will lead to fluctuation of 
the detected light with a frequency proportional to the particle speed. This information is 
transmitted to a digital signal processor and the potential zeta is calculated. Particles suspen-
sion normally are considered stable with zeta potentials greater than +30 mV or less than −30 
mV (Laouini, et al., 2012) (Popovska, et al., 2013). 
 The zeta potential of dispersed colloidal particles can be measured by electrophoresis. 
The electric force causes the particle to move in relation to a stationary liquid at a constant 
velocity. The ratio of the velocity to the electric field E is the electrophoretic mobility, μE. 
The mobility is converted into zeta potential, ζ, using the Smoluchowski equation: 
 
ζ = 
   
 
                                                            (4.5) 
where   is the viscosity of the solution and   is the permittivity of the solution (Laouini, et al., 
2012) (Popovska, et al., 2013). 
In this work, ZetaSizer Nano ZS (Malvern Instruments, Worcesterchire, UK) was used to 
measurements of zeta potential of the NPs in suspension.  It was used folded capillary cells 
from Malvern (Worcesterchire, UK) and the dispersant medium was water. Mean values for 
each preparation were obtained by duplicate measurements. Each measurement was per-
formed with 10 runs. 
 
4.1.5.2 –Dynamic Light Scattering 
Dynamic Light Scattering (DLS), also referred to as quasi-elastic light scattering, is a NPs 
characterization technique since it enables the determination of particles size and size distri-
bution in dispersions. The method is based on the fluctuations in the intensity of light scat-
tered by a small volume of a solution in the microsecond time range which are directly relat-
ed to the Brownian motion of the solute (Berne & Pecora, 1976). Submicrometer size particles 
in suspension exhibit significant random motion because of collisions with the molecules of 
the surrounding liquid medium called Brownian motion. As the result, when light irradiates a 
colloidal dispersion, the phases of the scattered waves fluctuate randomly in time. The scat-
tered light intensity from individual particles interfere with each other, and hence the net 
intensity of the scattered light fluctuates randomly in time (Boyd, et al., 2011) (Jiang & 
Oberdorster, 2009).  
 Diffusion is controlled by temperature (the higher the temperature, the faster the move-
ment), viscosity (the higher the viscosity, the slower the movement) and NPs size (the bigger 
the NPs, the slower the movement). Since the solvent and temperature during measurements 
are known and constant, it is possible to relate the variation of scattered light intensity to 
the NPs size (Jiang & Oberdorster, 2009). The Stokes-Einstein equation is used to determine 
NP size: 
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 ,                                                             (4.6) 
where RH is the hydrodynamic radius, k is the Boltzmann constant, T is the absolute tempera-
ture,   is the viscosity of the medium and D is the diffusion coefficient.  
 This relation is the basis of the particle size determination by DLS, but it is valid only for 
monodisperse particles. This measured size value refers to the hydrodynamic radius (HR). HR 
represents the size of a hypothetical sphere that moves the same way as the particle that is 
being measured, i.e. HR represents the NPs and its solvation shell.  Therefore HR will always 
be slightly than the real radius of the NPs. This solvation shell depends on the solvent, 
whereby successive measurements must always use the same solvent (Boyd, et al., 2011) 
(Jiang & Oberdorster, 2009). 
 In addition to the size, DLS also allows to determine the Polydispersity Index (PdI). PdI is 
an indicative of the heterogeneity of sizes of NPs in a suspension. A solution is monodisperse 
if the NPs have the same size. In this case, the PdI is less than 0.1. On the contrary, if the NPs 
have an inconsistent size, the dispersion is called a polydispersion. The presence of aggre-
gates can distort the results, since the equipment analyze them as single particle of bigger 
size, resulting in higher PdIs (Jiang & Oberdorster, 2009). 
 In this work, DLS measurements also were performed using a ZetaSizer Nano ZS (Malvern 
Instruments, Worcesterchire, UK). The size distribution was given by PdI. All the determina-
tions were performed in disposable cells (Sarstedt, Germany) and using water as dispersant 
medium. Mean values for each preparation were obtained by triplicate measurements. Each 
measurement was performed with 12 runs. 
 
4.1.6 – Morphologic Analysis of PLGA NPs 
 The morphological examination of the NPs was performed by transmission electron mi-
croscopy. 
 
4.1.6.1 – Transmission Electron Microscopy 
 Transmission electron microscopy (TEM) is arguably one of the most efficient and versatile 
tools for the characterization of nanomaterials morphology because gives real space images, 
including the surface and the internal structures of materials, tissues and cells. This micros-
copy has much higher resolution than conventional light microscope and is based on the prin-
ciple of electron wave–particle duality. As electron is a charged particle it can be accelerated 
in an electric field, and its trajectory can be deflected by electric and magnetic fields. As this 
accelerated electron also behave like wave, it is possible to control its wavelength by poten-
tial differences. The wavelength depends of velocity, as can be verified in the following 
equation: 
   
 
   
 ,                                              (4.7) 
where λ is the electron wavelength; h, the Planck’s constant; m, the electron mass; and v, 
the electron velocity. Therefore, depending on the accelerating voltage used, it is possible to 
choose the wavelength of the electron beam. The higher the accelerating voltage, the shorter 
the wavelength (Asadabad & Eskandari, 2015).  
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TEM is a microscopy technique wherein a beam of electrons is applied and is accelerated 
by an electric field formed by a voltage difference of, typically, 200 kV.  The set of condenser 
lenses focus the electron beam on strong magnetic fields to a spot on the sample to be inves-
tigated. Then the beam hits the sample and the electrons interact with the mater. Depending 
on the density of the sample, some of the electrons are scattered and some of them are 
transmitted through the sample. An image is formed from the electrons transmitted through 
the specimen, magnified and focused on an objective lens, and appears on an imaging screen 
(Figure 4.2) (Wang, 2000).  
 
 
 
Figure 4.2 – Image formation in transmission electron microscope. Adapted from (Cahn & Haasen, 1996) 
(Hiemenz & Rajagopalan, 1997). 
 
The objective diaphragm ensures the exclusion of inelastically scattered electrons in or-
der to enhance the image contrast. The beam that reaches the phosphor screen has different 
amounts of electrons that pass through particular regions of the sample. This difference is 
responsible for the image contrast. Darker areas of the image represent the regions of the 
sample through which fewer electrons were transmitted, due to the greater thickness or den-
sity. Contrariwise, brighter areas are the result of increased electronic transmission through 
the sample, i.e. representing thin regions of the sample (Asadabad & Eskandari, 2015). 
TEM was used to the morphological examination of the PLGA NPs. For that purpose, 5 μl 
of each sample was placed on carbon-formvar coated 200-400 mesh spacing grids (Agar Scien-
tific, UK) and let to adsorb for 5 minutes. The negative staining was performed with 2% (w/v) 
filtered aqueous solution of uranyl acetate for 45 seconds. The uranyl acetate solution was 
centrifuged at 12000 rpm for 3 minutes to pellet any unsolubilized uranyl acetate before use. 
After removing the excess of the negative staining solution and drying the grids, the samples 
were visualized using a Jeol JEM 1400 (Tokyo, Japan) electron microscope at 80 kV. 
  
34 
 
 
 
4.2 – Results and Discussion 
 
4.2.1 – Encapsulation Efficiency of Liposomes 
 Two techniques were used to remove free RES from liposome dispersions, dialysis and gel-
permeation chromatography, and thus calculate the encapsulation efficiency. In all ap-
proaches conducted, after separating the free RES from liposome dispersions and after burst-
ing liposomes with SDS, was not detected the characteristic peak of RES indicating that this 
was not encapsulated.  
The results of figure 4.3 demonstrated that after removing the free RES from liposome 
dispersions (Figure 4.3 b)), RES was not detected. This does not indicate in advance that the 
RES was not encapsulated because what was encapsulated cannot be detected within the lip-
osomes. Therefore, the liposomes were busted with SDS, but RES was not detected (Figure 
4.3 c)). The results of figure 4.3 are relative to the first approach performed, but the same 
results were obtained for the others approaches. 
Some studies confirmed the difficulty of encapsulating RES in liposomes. Neves, et al. de-
scribed the RES as potentially able to perturb membrane phospholipids possibly impairing or 
altering their structural and role (Neves, et al., 2012). The studies of Cao, et al. demonstrat-
ed that RES is located preferably in the liposome surface (Cao, et al., 2009). Bonechi, et al. 
also demonstrated that the RES was associated to the surface of the liposomes and not pene-
trated inside the liposomes (Bonechi, et al., 2012). Selvaraj, et al. concluded through their 
studies that stilbenes preferentially interact with the polar headgroups of the lipids. The 
authors showed that RES interacts with the lipid headgroup region of the bilayer and that RES 
is located at the superficie of liposomes (Selvaraj, et al., 2013). 
 So, this system for the encapsulation of RES- and extracts-loaded in liposomes was 
dropped. 
 
4.2.2 –Encapsulation Efficiency, Loading Capacity and Process Yield of PLGA 
NPs 
The obtained results for encapsulation efficiency (EE%) for both experimental conditions 
are expressed in percentages in table 4.3. EE% values achieved are according to our experi-
ence with other hydrophobic drugs (Frasco, et al., 2014) and other results reported in litera-
ture that state that EE values for PLGA NPs may vary from 6 to 90% (Danhier, et al., 2012). 
One reason for not having reached the higher values may be related to drug solubility in the 
surfactant solution (Hans & Lowman, 2002). As already reported in other studies, drugs can be 
incorporated into the core of the micelles formed by pluronic (Fessi, et al., 1989). As table 
4.3 shows, no significant changes of EE values (P>0.05) were observed for the both experi-
mental conditions for the encapsulation of the extracts. However for encapsulation of RES, 
the obtained values significantly increased (P≤0.05) with the second experimental condition, 
from 68±8 % to 80±6 %. This can be explained by better dissolution of resveratrol in acetone 
(Sun, et al., 2008). As RES showed a higher EE% the second experimental condition was se-
lected for the following experiments. 
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Figure 4.3 – UV-spectrum of liposomes alone and liposomes with RES a) before the separation of free 
RES, b) after the separation of free RES and c) busted with SDS after the separation of free RES. 
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Table 4.3 – Encapsulation efficiency values for both experimental conditions performed. In the first 
condition ethyl acetate was used for dissolving the drugs and in the second condition was used acetone. 
Data represented as mean ± SD (n=3). 
 
 
EE% 
RES-loaded PLGA NPs 
Grape seed extract-
loaded PLGA NPs 
Grape skin extract -
loaded PLGA NPs 
1st experimental 
condition 
68±8 74±3  73±9 
2nd experimental 
condition 
80±6 75±5 74±8 
 
The loading capacity of PLGA NPs was also evaluated. As expected, loading capacity val-
ues increased significantly (P≤0.05) with the extracts-loaded PLGA NPs in comparison with 
RES-loaded PLGA NPs (Table 4.4). RES-loaded NPs exhibited a loading capacity of 0.29±0.05 %, 
and the NPs loaded with grape seed and skin extracts have a loading of 5.8±0.4 % and 7.1±0.8 
%. This was already expected due to the reduced amount of RES used for preparing the PLGA 
NPs. PLGA NPs normally exhibit poor loading capacity (around 1% which means that NPs con-
tent 1 mg active ingredient per 100 mg polymers of NPs) (Danhier, et al., 2012). Thus, the 
values obtained in this experimental work are supported by the ones found in the literature as 
also by our experience with other hydrophobic drugs (Frasco, et al., 2014). 
The yield of this PLGA NPs production process is quite low with values of 3.4±0.4 % for 
RES-loaded PLGA NPS, 5.2±0.5 % for grape seed extract-loaded PLGA NPs and 6.6±0.7 % for 
grape skin extract-loaded PLGA NPs (Table 4.4). The values obtained in this experimental 
work are supported by other experiences that used acetone with solvent for de PLGA NPs 
preparation and a very low ratio between the drug and polymer (Murakami, et al., 1999). 
 
Table 4.4 – Loading capacity and process yield values for loaded PLGA NPs. Data represented as mean ± 
SD (n=2). 
 
 
RES-loaded PLGA NPs 
grape seed extract-
loaded PLGA NPs 
grape skin extract -
loaded PLGA NPs 
LC% 0.29±0.05 5.8±0.4 7.1±0.8 
PY % 3.4±0.4 5.2±0.5 6.6±0.7 
 
4.2.3 – Stability Studies of PLGA NPs 
The single emulsion solvent evaporation method allowed the encapsulation of RES, grape 
seed extract and grape skin extracts in the PLGA NPs. The attained results for mean diame-
ter, PdI and zeta potential, for the PLGA NPs loaded with RES, grape seed extract and grape 
skin extracts are shown in table 4.5. 
As it can be concluded after the analysis of table 4.5, the mean diameters of the loaded 
PLGA NPs ranged from 158 to 182 nm. That is, they were according to the expected values 
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because according with literature, PLGA NPs size is founded to be in the range of 100 to 250 
nm (Danhier, et al., 2012). As it is also shown in table 4.5, drug-loaded NPs exhibited a signif-
icantly larger size than unloaded PLGA NPs (P≤0.05), regardless of whether it was encapsulat-
ed RES, grape seed extract or grape skin extracts. The size increased from 161 ± 3 nm to 179 
± 3 nm, 178 ± 2 nm and 175 ± 1 nm, respectively. This effect was reported in studies that ar-
gue that the drug causes an expansion of the polymeric matrix, increasing particle size 
(Musumeci, et al., 2006). The prepared systems exhibited a narrow size distribution (PdI ≤ 
0.1). 
 
Table 4.5 – Physicochemical features of RES, grape seed extract and grape skin extract-loaded PLGA NPs. 
Data represented as mean ± SD (n=2). 
 
PLGA NPS 
Mean Diameter 
(nm) 
PdI 
Zeta Potential 
(mV) 
Unloaded 
161±3 0.05±0.03 - 31±2 
RES-loaded 
179±3  0.09±0.02 - 26±2  
Grape seed extract-loaded 
178±2  0.05±0.03 - 28±1  
Grape skin extract -loaded 175±1  0.06±0.01 - 26±1  
 
Zeta potential values for PLGA NPs are negative as expected, ranging from -33 to -24 mV, 
due to their carboxylic end-groups, as it is shown in table 4.5. Zeta potential absolute value 
significantly decreased from 31.2 mV in unloaded PLGA NPs to 26.1, 27.5 and 26.4 mV in RES-
loaded, grape seed extract-loaded PLGA NPs and grape skin extract-loaded PLGA NPs respec-
tively (P≤0.05). These values could be explained by drug adsorption on PLGA NPs surface. 
As already reported by Musumeci, et al., the drug adsorbed on PLGA NPs surface exert a 
masking effect of the superficial carboxylic groups, reducing the effective NP charge 
(Musumeci, et al., 2006). This masking effect could also explain the decrease, although not 
significant (P>0.05), in zeta potential values. Moreover, zeta potential values were not signif-
icantly different between the drugs used for preparation NPs (P>0.05). 
In order to study the stability of the PLGA NPs over time, their mean diameter, PdI and 
zeta potential values were measured during 1 month. Stability tests are presented in table 
4.6. Mean size variation is expressed in terms of ratio St/Si. 
Over this time, there were no significant variations on these parameters, which indicate 
that the PLGA NPs are stable. It is very important to certify that the vesicles are not aggre-
gated, since the size and stability of PLGA NPs are critical for their cell internalization. RES-
loaded NPs exhibited a mean St/Si value of 0.993 for approximately 1 month, while grape seed 
extract-loaded presented a value of 1.01 and grape skin extract-loaded of 1.03. The 
monodisperse RES-, grape seed extract- and grape skin extract-loaded PLGA NPs showed mean 
sizes of 179±2 nm, 181±4 nm and 176±1 nm, respectively, which have remained constant over 
time. The size distribution (PDI  0.1) of all preparation indicates the formation of uniform 
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structures. These data proves that the NPs remained physically stable at storage conditions (4 
ºC) for approximately 1 month. 
Zeta potential values showed a slight decrease (no significantly different (P>0.05)) over 
time (table 4.6). However as applying an electric field to the sample may alter it, only values 
for size were considered for stability evaluation purposes. 
 
Table 4.6 – Zeta potential, mean diameter and PdI values for loaded PLGA NPs, over a period of 1 
month. Mean size variation is expressed in terms of ratio St/Si, where St is mean diameter after t days of 
storage and Si is the NPs initial mean size. Data represented as mean ± SD (n=3 for mean diameter and 
PdI and n=2 for zeta potential). These data is only relative to one batch for each formulation, loaded 
and unloaded. 
 
PLGA NPs 
Mean diameter 
(nm) 
Ratio St/Si PdI 
Zeta Potential 
(mV) 
RES-loaded 
 
Day 1 179 ± 2 nm - 0.039 ± 0.021 -26.1 ± 1.8 mV 
Day 7 175 ± 4 nm 0.978 0.042 ± 0.012 -25.1 ± 0.8 mV 
Day 14 177 ± 6 nm 0.989 0.056 ± 0.029 -22.5 ± 0.3 mV 
Day 28 181 ± 5 nm 1.011 0.075 ± 0.015 -21.8 ± 0.7 mV 
Grape seed 
extract-loaded 
 
Day 1 181 ± 4 nm - 0.065 ± 0.024 -24.6 ± 0.9 mV 
Day 7 185 ± 3 nm 1.022 0.034 ± 0.014 -23.9 ± 0.5 mV 
Day 14 182 ± 9 nm 1.006 0.047 ± 0.017 -23.5 ± 1.1 mV 
Day 28 183 ± 2 nm 1.011 0.056 ± 0.019 -22.4 ± 0.7 mV 
Grape skin ex-
tract-loaded 
 
Day 1 176 ± 1 nm - 0.056 ± 0.014 -26.4 ± 0.3 mV 
Day 7 177 ± 1 nm 1.011 0.055 ± 0.020 -25.9 ± 0.1 mV 
Day 14 183 ± 5 nm 1.046 0.037 ± 0.018 -23.5 ± 0.3 mV 
Day 28 182 ± 3 nm 1.040 0.046 ± 0.017 -24.5 ± 0.9 mV 
 
4.2.4 – Morphologic Analysis of PLGA NPs 
TEM analysis of PLGA NPs revealed spherical and uniform shaped NPs, as it is shown in fig-
ure 4.4. The diameter of the NPs is in conformity with the size measurement by DLS. These 
images also show a relatively monodisperse NPs. 
NPs’ stability is a result of the electrostatic forces due to the PLGA carboxylate groups at 
the NP surface, and the surfactant behavior that also plays a crucial role in maintaining 
nanosuspension stabilization. During particle formation, the stabilizer is able to modify NPs 
stabilization (Trump, et al., 2010) by adsorbing onto the NP surface (Wolpin, et al., 2012). In 
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fact, in figure 10, a morphologic examination performed by TEM shows a pluronic layer sur-
rounding PLGA NPs. The surfactant causes steric repulsions forming a mechanic barrier pro-
hibiting droplet approaching. Thermodynamic stabilization can also be considered, due to a 
loss of configurational entropy of surface adsorbed pluronic when overlapping occurs for ap-
proaching droplets (Wilczewska, et al., 2012). For all those reasons, it can be concluded that 
the method followed for the preparation of PLGA NPs produced well-stabilized monodisperse 
NPs. 
 
 
 
 
 
 
 
 
Figure 4.4 – TEM images of unloaded PLGA NPs. The scale bars correspond to (A) 200 nm and (B) 100 nm. 
The red arrow indicates the pluronic layer surrounding the PLGA NPs. 
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Chapter 5 
 
 
Interaction of A  with Resveratrol and 
Extracts of Grape Seed and Skin 
 
 
 
The aggregation process of the Aβ peptide leads to the formation of insoluble fibrils which 
accumulate in senile plaques, deposits that characterize AD (Clippingdale, et al., 2001) 
(Klafki, et al., 2006) (Selkoe, 2001). The more abundant sequences of the peptide have 40 
(~90%), Aβ(1-40), and 42 (~10%), Aβ(1-42), amino acids (Lee, et al., 2004). The peptide with 42 
amino acids is more toxic ant it is the major component of the neuritic plaques found in AD 
(Hardy & Selkoe, 2002) (Lee, et al., 2004). The smaller aggregated intermediates, the Aβ oli-
gomers, are considered the more toxic species (Hardy & Selkoe, 2002). The imbalance be-
tween Aβ production and its clearance leads to the Aβ aggregation in the brain, that plays a 
key role in the development of AD (Li, et al., 2012). 
Insoluble fibrillar protein aggregates are considered a pathological feature of several neu-
rodegenerative diseases. Protein misfolding or partially folded structure is responsible for the 
fibrillation of various amyloidogenic proteins/peptides (Ahn, et al., 2007). Thus, it is essential 
to find molecules that prevent or interrupt the aggregation of proteins (Feng, et al., 2009). 
Various natural compounds have been suggested as therapeutics for AD and PD. Among these 
compounds, RES arouses great interest (Amri, et al., 2012). Several studies have demonstrat-
ed that RES is capable of preventing a variety of disorders, including cardiovascular diseases, 
cancer, diabetes, arthritis and neurodegenerative diseases. Given the benefits of RES, it is 
believed that it is useful in the therapy of AD and PD (Gusman, et al., 2001). RES has anti-
amyloidogenic activity because it promotes the intracellular degradation of Aβ by a mecha-
nism involving the proteasome, thereby reducing levels of Aβ (Marambaud, et al., 2005). 
 This chapter relates to the interaction between different drugs (RES and extracts of grape 
seed and skin) and Aβ peptide. 
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5.1 – Material and Methods 
 
5.1.1 – Amyloid-Beta Peptides 
 Aβ(1-42) (amyloid-β peptide 1-42, purity > 95%, MW 4514.14) was purchased from Selleck 
Chemicals (Houston, Texas, USA) (Figure 5.1). The aggregation state and the structure of the 
peptide are highly dependent on the sample batch (Soto, et al., 1995). To improve peptide 
solubility and disaggregate pre-formed agglomerates, the peptide was dissolved in 100% 
1,1,1,3,3,3- hexafluoro-2-propanol (HFIP, purity ≥ 99.8%, Sigma-Aldrich, Germany) at 1 
mg/mL concentration and kept at room temperature for 1–2 h. HFIP was evaporated with ni-
trogen flow and under vacuum. The peptide film with the Aβ(1-42) in a monomeric structure 
was dissolved in dimethyl sulfoxide for molecular biology (DMSO, purity ≥ 99.9%, MW 78.13, 
Sigma-Aldrich, Germany) at 9 mg/mL concentration. Aβ(1-42)  solution is stored at -20 °C (Nils-
son, 2004) (Rocha, et al., 2009) (Sabaté & Estelrich, 2005). 
Figure 5.1 – Amino acids of the Aβ peptide used in this study and their secondary structure prediction. 
 
5.1.2 – Stock Solutions of Resveratrol, extracts of grape seed and skin and 
loaded-PLGA NPs 
 Stock solutions of RES (purity ≥ 99%, MW 228.24, Sigma-Aldrich) and extracts of the grape 
seed and grape skin (purity ≥ 95%, Monteloeder) were prepared as is described in the Chapter 
3, Section 3.1.1. 
 Stock solutions of loaded-PLGA NPs were prepared as is described in the Chapter 4, Sec-
tion 4.1.2. 
 
5.1.3 – Fluorescence Measurements 
 Fluorescence occurs when a molecule absorbs light photons from the UV-visible light spec-
trum (200-900 nm), known as excitation, causing transition to a high-energy electronic state, 
and then rapidly emits light photons as it returns to its ground state, in less than 10-9 seconds. 
The processes that occur between the absorption of light and its emission are represented 
conveniently in the Jablonski diagram (Figure 5.2) (Lakowicz, 1988) (So & Dong, 2002).  
 Some molecules emit fluorescence naturally while others can be modified to yield fluo-
rescent compounds. The fluorescent compounds exhibit two characteristic spectra: an excita-
tion spectrum and an emission spectrum. Don't have two compounds that have the same spec-
trum which makes fluorometry a highly specific analytical technique (So & Dong, 2002). 
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Figure 5.2 – Jablonski diagram. 
 
where S0, S1, S2 are the singlet ground, first and second electronic states, respectively; A’, 
the photon absorption; F, the fluorescence (emission) and IC, the internal conversion. 
 The fluorescence measurement technique is designated fluorometry and the instrument 
used is called a fluorometer or fluorimeter. Fluorometry is a type of electromagnetic spec-
troscopy, which analyzes fluorescence from a sample and characterizes the relationship be-
tween absorbed and emitted photons at specified wavelengths. A fluorimeter generates the 
wavelength of light needed to excite the electrons in molecules of the sample; selectively 
transmitting the wavelength of the emitted light (not necessarily visible light), and then 
measures the intensity of the emitted light. Up to a maximum concentration, the emitted 
light is proportional to the concentration of the sample measured. Normally, the amount of 
fluorescence energy emitted is only 3% of the amount of excitation light energy. Fluorescence 
light has a lower energy (higher wavelength) than the excitation energy and is usually scat-
tered light (Lakowicz, 1988) (So & Dong, 2002). 
 The fluorometry has several advantages such as high sensitivity and specificity, simplicity 
and low cost, so it is widely used for a variety of applications. This technique is about 1000 
times more sensitive than absorbance measurements becoming an asset to quantitative and 
qualitative analysis. 
 
5.1.3.1 – Thioflavin T Binding Assay 
 Thioflavin T (ThT) is a cationic benzothiazole, a classic amyloid dye that is commonly 
used to probe Aβ fibril formation because of its strong fluorescence emission upon binding to 
amyloid fibril structures (Khurana, et al., 2005) (Kuznetsova, et al., 2012) (Nilsson, 2004). 
ThT is used to identify and quantify of amyloid fibrils as well as for the exploration of 
fibrillization kinetics of Aβ in the presence of small molecules. It is presumed that the quanti-
ty the amyloid fibrils is proportional to the intensity of fluorescence (Biancalana & Koide, 
2010) (Jameson, et al., 2012).  
 For ThT assays, a ThT stock solution was prepared by adding 8 mg of ThT (Sigma-Aldrich, 
Germany) to 10 ml of PBS (Nilsson, 2004). This solution was filtered through a 0.2 μm syringe 
filter and diluted (9 ml of ThT stock solution in 50 ml of PBS) (ThT working solution). To pre-
pare specimens for kinetic studies, Aβ peptide (25 μM) was incubated in the presence or ab-
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sence of RES, grape seed extract and grape skin extract at the same concentrations (40 and 
80 μM) in PBS, for 10 days at 37°C. Aβ peptide (25 μM) was also incubated in the presence or 
absence of RES-, grape seed extract- and grape skin extract-loaded PLGA NPs at the same 
concentrations (40 μM) in PBS, for 10 days at 37°C. For the kinetic studies of the Aβ peptides 
in the absence and presence of the RES and extracts of the grape seed and grape skin free 
and loaded in PLGA NPs, 72 μl of the samples were added to 8 μl of the ThT working solution. 
The samples were placed on a 96-well plate (Nunclon Delta Surface) and the fluorescence 
intensity was measured using a BioTek® Synergy 2 Multi-Mode reader (Winooski, Vermont, 
USA) after stirring 30 seconds at 37 °C every 20 minutes during 10 days. The spectra were 
subtracted to the controls (ThT working solution, drugs and PLGA NPs). The measurements 
were performed with a 420/50 nm excitation filter and a 485/20 nm emission filter.  
 
5.1.4 – Transmission Electron Microscopy 
 Transmission electron microscopy (TEM) is used to detect the presence of fibrils. To pre-
pare specimens for TEM imaging, Aβ peptide (25 μM) was incubated in the presence or ab-
sence of RES, grape seed extract and grape skin extract free and loaded in PLGA NPs at the 
same concentrations (40 and 80 μM for free drugs and 40 μM for drugs-loaded PLGA NPs) in 
PBS, for 7 days at 37ºC. For the ultra-structural studies of the Aβ peptides in the absence and 
presence of the RES and extracts of the grape seed and grape skin free and loaded in PLGA 
NPs, 5 μL of each sample was placed on carbon-formvar coated 200-400 mesh spacing grids 
(Agar Scientific, UK) and let to adsorb for 5 minutes. The negative staining was performed 
with 2% (w/v) filtered aqueous solution of uranyl acetate for 45 seconds. The uranyl acetate 
solution was centrifuged at 12000 rpm for 3 minutes to pellet any unsolubilized uranyl ace-
tate before use. After removing the excess of the negative staining solution and drying the 
grids, the samples were visualized using a Jeol JEM 1400 (Tokyo, Japan) electron microscope 
at 80 kV. 
 
 
5.2 – Results and Discussion 
 
5.2.1 – Interaction of A  with Resveratrol and Extracts of Grape Seed and Skin 
 Initially, the aggregation of Aβ(1-42) was studied in the absence and presence of RES and 
extracts of the grape seed and grape skin at a peptide concentration of 25 μM and RES, grape 
seed extract and grape skin extract at two different concentrations (40 and 80 μM) in PBS, for 
10 days at 37 °C.  To evaluate the inhibitory activities of RES, extract of the grape seed and 
extract of the grape skin, against Aβ(1-42) aggregation, ThT fluorescence binding assay and TEM 
were performed.  
 ThT binding assay results (Figure 5.3 and Figure 5.4) demonstrated that a significant bind-
ing to ThT is observed for Aβ(1-42) incubated alone. The fluorescence intensity at 450 nm, 
which is the characteristic excitation maximum observed upon ThT binding, increased after 6 
hours incubation time at 37 °C. The results indicated that the intensity of fluorescence of RES, 
extract of the grape seed and extract of the grape skin was low. These results reveal that RES 
and the extracts of the grape seed and skin inhibit the Aβ(1-42) fibril formation. The results 
indicated that the extracts have a more pronounced inhibitory effect in comparison with RES. 
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All samples reached a stable signal after approximately 10 hours incubation. At the concen-
tration of 40 μM, RES inhibits around 86% of the aggregation of the peptide, the grape skin 
extract inhibits around 92% and the grape seed extract inhibits around 97%. At the concentra-
tion of 80 μM, these values increased 91, 97 and 98%, respectively.  As the figures 5.3 and 5.4 
show, no significant changes of percentage of the peptide aggregation (P>0.05) were ob-
served for the both concentrations used. These results suggest that beyond to contain RES 
that inhibits the aggregation of Aβ(1-42), the extracts have other polyphenols that make this 
inhibitory effect most pronounced. 
 The results in Figure 5.5 were consistent with the ThT binding assay. TEM images demon-
strated that in the absence of RES or extracts Aβ(1-42) showed fibril formation whereas in the 
presence of RES or extracts, the samples appeared to be devoid of those structures. When 
Aβ(1-42) was co-incubated with RES and extracts, the number of fibrils decreased, there were 
numerous oligomers present in the samples but only small aggregates are observed, indicating 
the inhibit the Aβ(1-42) fibrillogenesis. 
 Marambaud, et al. tried to determine if RES causes the decrease of Aβ levels. To this end, 
they treated APP695-transfected HEK293 cells with increasing concentrations of RES and ana-
lyzed Aβ levels by ELISA and Western Blot (WB). Total secreted Aβ, including Aβ(1-40) and Aβ(1-
42), were markedly reduced by 20 – 40 μM RES after 24 hours of incubation. To determine 
whether the effect of RES is time-dependent, APP695-HEK293 cells were treated for different 
periods of time. RES did not affect Aβ levels after 12 hours of incubation. The same results 
related to the incubation time were achieved by ThT fluorescence essay as showed in figures 
5.3 and 5.4. Their data showed that RES strongly reduces Aβ produced by different cell lines 
expressing wild type or Swedish mutant APP695 (Marambaud, et al., 2005). 
 Hung, et al. studied the Aβ(1-40) aggregation in the presence and absence of RES using ThT 
and TEM. The concentration of Aβ(1-40) and RES used was 50 μM. In the presence of RES, the 
fluorescence intensity was greatly attenuated. Both samples (Aβ(1-40) alone and Aβ(1-40) with 
RES) reached a stable signal after 144 hours. Structural modification of Aβ(1-40) by RES was also 
imaged using TEM with samples incubated for 7 days at 37°C. Fibril networks of Aβ(1-40) have 
been observed  in the absence of RES. In the presence of RES, the samples appeared to be 
devoid of those structures (Hung, et al., 2013). The TEM images obtained in Hung, et al. study 
were similar with Figure 5.5 wherein after incubation of Aβ(1-42) with RES also revealed a de-
crease of number of fibrils. 
 To study the effects of different concentrations of RES in inhibition of the formation of 
Aβ(1-42)  aggregates, Feng, et al. mixed Aβ(1-42) with RES and monitored Aβ(1-42) aggregation us-
ing ThT. When Aβ(1-42) at a concentration of 10 μM was co-incubated with 2, 10, and 100 μM of 
RES, the level of fluorescence decreased in a concentration-dependent way, where 100 μM of 
RES inhibited around 90% of aggregation, 2 and 10 μM of RES inhibited 30% and 50% of fluores-
cence intensity, respectively, after 14 hours of incubation at 37 °C. The percentage of inhibi-
tion of aggregation obtained in this study at 100 μM of RES was similar to that obtained in this 
study using RES at 80 μM. In order to detect the morphologies of Aβ(1-42) aggregates, the same 
authors used TEM to probe the aggregation process in the presence or absence of RES. When 
Aβ(1-42) was incubated alone for 3 days, robust fibrils were observed. However when Aβ(1-42) 
was co-incubated with 10 μM and 100 μM of RES for 3 days, the number of fibrils decreased 
with increasing concentration of RES. At 100 μM, were observed numerous oligomers present 
in the samples but few fibrils were observed. TEM imaging was consistent with above fluores-
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cence results (Feng, et al., 2009). Similar TEM analysis was observed as illustrated in Figure 
5.4 using RES at 80 μM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 –Effect of the RES and extracts of the grape seed and grape skin on Aβ(1-42) fibrils content as 
monitored by ThT fluorescence. The Aβ(1-42) concentration was 25 μM and the drugs concentration was 40 
μM. The samples were incubated at 37°C for 10 days in the presence or absence of RES and extracts of 
the grape seed and grape skin in PBS buffer. 
 
 
 
Figure 5.4 – Effect of the RES and extracts of the grape seed and grape skin on Aβ(1-42) fibrils content as 
monitored by ThT fluorescence. The Aβ(1-42) concentration was 25 μM and the drugs concentration was 80 
μM. The samples were incubated at 37°C for 10 days in the presence or absence of RES and extracts of 
the grape seed and grape skin in PBS buffer. 
0 
0,1 
0,2 
0,3 
0,4 
0,5 
0,6 
0,7 
0,8 
0,9 
1 
0 6 10 24 72 168 240 
N
o
rm
a
li
z
e
d
 F
lu
o
re
sc
e
n
c
e
 I
n
te
n
si
ty
 
Time (hours) 
AB AB with RES AB with Grape skin extract AB with Grape seed extract 
0 
0,1 
0,2 
0,3 
0,4 
0,5 
0,6 
0,7 
0,8 
0,9 
1 
0 6 10 24 72 168 240 
N
o
rm
a
li
z
e
d
 F
lu
o
re
sc
e
n
c
e
 I
n
te
n
si
ty
 
Time (hours) 
AB AB with RES AB with Grape skin extract AB with Grape seed extract 
  
 
   47                                                                                                                         
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 – Transmission electron microscopy of the effect of the RES and extracts of the grape seed 
and grape skin on Aβ(1-42) aggregation. The Aβ(1-42) concentration was 25 μΜ and the drugs concentration 
was 80 μM. The samples were incubated for 10 days at 37 °C in the presence or absence of RES and ex-
tracts of the grape seed and grape skin in PBS buffer. The scale bar corresponds to 100 nm. 
 
 Considering the results obtained, this natural compound could be a promising molecule 
for the development of therapeutics for prevent or treat AD. 
 The aggregation of Aβ(1-42) was also studied in the presence of loaded-PLGA NPs at a pep-
tide concentration of 25 μM and drugs concentrations of 40 μM in PBS, for 10 days at 37 °C.  
To evaluate the inhibitory activities of loaded-PLGA NPs against Aβ(1-42) aggregation, ThT fluo-
rescence binding assay and TEM were performed. 
ThT binding assay results (Figure 5.6) demonstrated that a significant binding to ThT is 
observed for Aβ(1-42) incubated alone. The fluorescence intensity at 450 nm, which is the char-
acteristic excitation maximum observed upon ThT binding, increased after 6 hours incubation 
time at 37 °C. The results indicated that the intensity of fluorescence of Aβ(1-42) with drug-
loaded PLGA NPs was lower in comparison with Aβ(1-42) alone. These results reveal that drug-
loaded PLGA NPs inhibit the Aβ(1-42) fibril formation. The results indicated that the extracts-
loaded PLGA NPs have a more pronounced inhibitory effect in comparison with RES-loaded 
PLGA NPs. After approximately 6 hours incubation, all samples showed a slow decrease of 
normalized fluorescence intensity. At the concentration of 40 μM, RES-loaded PLGA NPs inhib-
its around 46% of the aggregation of the peptide, the grape skin extract-loaded PLGA NPs in-
hibits around 52% and the grape seed extract-loaded PLGA NPs inhibits around 56%, after 10 
days of incubation. 
The results in Figure 5.7 were consistent with the ThT binding assay. TEM images demon-
strated that in the absence of RES or extracts Aβ(1-42) showed fibril formation. In the presence 
of RES or extracts, the samples in the presence of the drug, the quantity of fibers present in 
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the samples appears to be lower with the observation oligomers and protofibrils, indicating 
the inhibit the Aβ(1-42) fibrillogenesis. 
 
 
 
Figure 5.6 – Effect of loaded-PLGA NPs on Aβ(1-42) fibrils content as monitored by ThT fluorescence. The 
Aβ(1-42) concentration was 25 μM and the drugs concentration was 40 μM. The samples were incubated at 
37°C for 10 days in the presence or absence of loaded-PLGA NPs in PBS buffer. 
 
 
 
Figure 5.7 – Transmission electron microscopy of the effect of the loaded-PLGA NPs on Aβ(1-42) aggrega-
tion. The Aβ(1-42) concentration was 25 μΜ and the drugs concentration was 40 μM. The samples were 
incubated for 14 days at 37 °C in the presence or absence of loaded-PLGA NPs in PBS buffer. The scale 
bar corresponds to 200 nm.  
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Chapter 6 
 
 
Concluding Remarks and Future Perspec-
tives  
 
 
 
The AD, a neurodegenerative disorder, is promoted by the increase of the age. This dis-
ease is a progressive disease and is characterized by loss of memory and cognitive impairment, 
loss of language and behavior changes. The neuropathological characteristics of AD include 
extracellular senile plaques, which consist of deposits of Aβ and neurofibrillar tangles that 
are formed by hyperphosphorilation and abnormal deposition of tau protein (Clippingdale, et 
al., 2001) (Klafki, et al., 2006) (Selkoe, 2001). The imbalance between Aβ production and its 
clearance leads to the Aβ aggregation in the brain, that plays a key role in the development 
of AD (Li, et al., 2012). 
Insoluble fibrillar protein aggregates are considered a pathological feature of AD. Protein 
misfolding or partially folded structure is responsible for the fibrillation of various 
amyloidogenic proteins/peptides (Ahn, et al., 2007). Thus, it is essential to find molecules 
that prevent or interrupt the aggregation of proteins (Feng, et al., 2009). 
RES arouses great interest because has interesting biochemical and physiological proper-
ties (Ahn, et al., 2007) (Amri, et al., 2012) (Baur & Sinclair, 2006). Several studies have 
demonstrated that RES is capable of preventing a variety of disorders, including cardiovascu-
lar diseases, cancer, diabetes, arthritis and neurodegenerative diseases. Given the benefits of 
RES, it is believed that it is useful in the therapy of AD and PD (Gusman, et al., 2001). RES has 
anti-amyloidogenic activity because it promotes the intracellular degradation of Aβ by a 
mechanism involving the proteasome, thereby reducing levels of Aβ (Marambaud, et al., 
2005). 
A growing effort has being applied to find novel approaches for neurodegenerative treat-
ment and in recent years a growing number of studies, focused on the research and develop-
ment of NPs as drug delivery systems, have been conducted (Wilczewska, et al., 2012). Nano-
particles are promising candidates for drugs delivery, as they present numerous advantages 
over conventional chemotherapy such as improving the drug water solubility, protecting it 
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from the macrophage uptake, thus enhancing the blood circulation time, and finally providing 
an increased and controlled release into the specific final target. 
Liposomes and PLGA have different physico chemical, biochemical and mechanical prop-
erties each presenting their own advantages where drug delivery is concerned. For this reason, 
in this work, liposomes and PLGA NPs were proposed to drug delivery to AD. 
Drug-loaded liposomes were not able to encapsulate RES and extracts, no significant val-
ues of encapsulation efficiency were obtained for these nanocarriers.  
Drug-loaded PLGA NPs were prepared by a single emulsion solvent evaporation method 
and stabilized with Pluronic® F-127. Two experimental conditions were tested and discussed 
using RES and extracts of grape seed and skin as a drug model to select the NP that presents 
adequate physicochemical characteristics for the drugs encapsulation and delivery. The pre-
pared PLGA NPs exhibit a spherical shape, mean diameter ranging between 158 to 182 nm, 
low PdI values and negative zeta potential values. While RES entrapment reached values of 
efficiency of approximately 80±6 %, for grape seed and skin extracts-loaded PLGA NPs the 
attained encapsulation efficiency values were slightly lower, 75±5 % and 74±8 %, respectively. 
The prepared NPs exhibited loading capacity values in the order of 0.3-7 % and a process yield 
in the order of 3.4-6.6 %. The prepared system is stable at storage conditions for one month.  
ThT binding assay and TEM results demonstrated that RES, extract of the grape seed and 
extract of the grape skin inhibit the Aβ(1-42) fibril formation. The results indicated that the 
extracts have a more pronounced inhibitory effect in comparison with RES. At the concentra-
tion of 40 μM, RES inhibits around 86% of the aggregation of the peptide, the grape skin ex-
tract inhibits around 92% and the grape seed extract inhibits around 97%. At the concentra-
tion of 80 μM, these values increased for 91, 97 and 98%, respectively.  No significant changes 
of percentage of the peptide aggregation (P>0.05) were observed for the both concentrations 
used. These results suggest that beyond to contain RES that inhibits the aggregation of Aβ(1-42), 
the extracts have other polyphenols that make this inhibitory effect most pronounced. 
The studies proved that drug-loaded PLGA NPs inhibit the Aβ(1-42) fibril formation. The re-
sults indicated that the extracts-loaded PLGA NPs have a more pronounced inhibitory effect 
in comparison with RES-loaded PLGA NPs. At the concentration of 40 μM, RES-loaded PLGA 
NPs inhibits around 46% of the aggregation of the peptide, the grape skin extract-loaded PLGA 
NPs inhibits around 52% and the grape seed extract-loaded PLGA NPs inhibits around 56%, af-
ter 10 days of incubation. 
All these results suggest that the obtained NPs could be good candidates for RES and ex-
tracts of grape seed and skin release. The nanoencapsulation in PLGA NPs may offer a new 
and potentially effective administration strategy of RES and extracts of grape seed and skin 
that overcomes the actual limitations as its bioavailability and toxicity. But, the optimization 
of NPs must be performed. 
Several assays and experiments could have been conducted to upgrade the developed sys-
tem as to improve its characterization, but were not possible to perform due to time re-
strictions. Although, the prepared PLGA NPs have proved to be a promising new approach to 
RES and extracts of grape seed and skin delivery to AD, further development is required. The 
optimization of NPs must be performed in order to increase the therapeutic potential of the 
drugs under study. For instance surface modification, with specific biomolecules or antibodies, 
may improve their targeting and accumulation in target-tissue as increase their bioavailability. 
Finally, in vivo tests using animal models would be interesting to evaluate in detail the system 
efficacy. However these studies would entail a costly investment. 
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Appendix 
 
 
 
Appendix 1 - Calibration curve of RES using BioTek® Synergy 2 Multi-Mode Reader (n=3). 
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Appendix 2 - Calibration curve of RES using UV-1700 PharmaSpec UV-VIS Spectrophotometer Shimadzu 
(n=3). 
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